<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00824265</url>
  </required_header>
  <id_info>
    <org_study_id>110913</org_study_id>
    <nct_id>NCT00824265</nct_id>
  </id_info>
  <brief_title>Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects With Relapsed Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of ofatumumab added to
      fludarabine-cyclophosphamide in patients with relapsed Chronic Lymphocytic Leukemia (CLL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fludarabine is currently approved for treatment of relapsed Chronic Lymphocytic Leukemia.
      Studies have shown that drugs in combination with fludarabine have shown more effectiveness
      than fludarabine alone. The addition of ofatumumab to fludarabine-cyclophosphamide
      combination offers potentially a more effective therapy, without additional toxicity.

      The objective of this study is to determine the effect of ofatumumab added to fludarabine and
      cyclophosphamide in patients with Chronic Lymphocytic Leukemia who have responded previously
      to therapy but later develop progressive disease and require additional therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">October 25, 2017</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS), as Assessed by the Independent Review Committee (IRC)</measure>
    <time_frame>From randomization up to 5 years after last dose of study drug</time_frame>
    <description>PFS is defined as the interval of time between the date of randomization and the earlier of the date of disease progression (progressive disease,PD) and the date of death due to any cause. PD requires at least one of the following: lymphadenopathy, appearance of any new lesion such as enlargerd lymph nodes (&gt;1.5 cm) spleen or liver or other infiltrates or an increase by 50% or more in the greatest diameter of any previous site; an increase by 50% or more in the previously noted enlargement of the liver or spleen, an increase by 50% or more in the numbers of blood lymphocytes with at least 5000 lymphocytes per microliter, transformation to a more aggressive histology, or occurrence of cytopenia attributable to chronic lymphocytic leukaemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From randomization up to 5 years after last dose of study drug</time_frame>
    <description>Overall survival is defined as the time from randomization to death due to any cause. Each participant was followed at the time when the last IRC-assessed PFS events occurred. Participants who had not died were censored at the date of last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response, as Assessed by the IRC</measure>
    <time_frame>From randomization up to 5 years after last dose of study drug</time_frame>
    <description>Time to response is defined as the time from randomization to the first response. Complete Response/remission(CR) all the criteria at least 2 months after last treatment: no lymphadenopathy(Ly) &gt; 1.5 cm/ hepatomegaly/spleenomegaly/constitutional symptoms; neutrophils &gt;1500 per microliter(µL), platelets(PL) &gt;100,000/µL, hemoglobin(Hb) &gt;11 grams/deciliter(g/dL), lymphocytes(LC) &lt;4000/µL, bone marrow(BM) sample must be normocellular for age, &lt;30% LC, no lymphoid nodule. Incomplete bone marrow recovery(CRi): CR criteria, persistent anemia/thrombocytopenia/neutropenia unrelated to CLL but related to drug toxicity. Partial Remission/response(PR): &gt;=50% decrease in LC, Ly, size of liver and spleen and at least one of the following results: PL &gt;100,000/µL or 50% improvement over Baseline(BL), Hb &gt;11 g/dL or 50% improvement over BL. Nodular PR(nPR): persistent nodules BM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR), as Assessed by the IRC</measure>
    <time_frame>From time of initial response to disease progression or death, whichever came first (up to 5 years after the last dose of study drug)</time_frame>
    <description>DOR is defined as the time from the initial response (CR, CRi, nPR, or PR) to the first documented sign of PD or death due to any cause. PD requires at least one of the following: lymphadenopathy, appearance of any new lesion such as enlargerd lymph nodes (&gt;1.5 cm) spleen or liver or other infiltrates or an increase by 50% or more in the greatest diameter of any previous site; an increase by 50% or more in the previously noted enlargement of the liver or spleen, an increase by 50% or more in the numbers of blood lymphocytes with at least 5000 lymphocytes per microliter, transformation to a more aggressive histology, or occurrence of cytopenia attributable to chronic lymphocytic leukaemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression, as Assessed by the IRC</measure>
    <time_frame>From randomization up to 5 years after the last dose of study drug</time_frame>
    <description>Time to progression is defined as the time from the date of randomization to PD. PD requires at least one of the following: lymphadenopathy, appearance of any new lesion such as enlargerd lymph nodes (&gt;1.5 cm) spleen or liver or other infiltrates or an increase by 50% or more in the greatest diameter of any previous site; an increase by 50% or more in the previously noted enlargement of the liver or spleen, an increase by 50% or more in the numbers of blood lymphocytes with at least 5000 lymphocytes per microliter, transformation to a more aggressive histology, or occurrence of cytopenia attributable to chronic lymphocytic leukaemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Next Therapy</measure>
    <time_frame>From the start of study drug until the start of the next anti-CLL therapy (up to 5 years after the last dose of study drug)</time_frame>
    <description>Time to next therapy is defined as the time from randomization until the start of the next-line of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Improvement in Eastern Cooperative Oncology Group (ECOG) Performance Status</measure>
    <time_frame>Cycle 2 Day1, Cycle 3 Day1, Cycle 4 Day1, Cycle 5 Day1, Cycle 6 Day1, follow up (FU) at 1Month (M) after study drug therapy, then every 3 month up to 5 year (up to 60 months)</time_frame>
    <description>The ECOG performance status scales and criteria are used by doctors and researchers to assess how a participant's disease is progressing, how the disease affects the daily living, and determines appropriate treatment and prognosis. ECOG performance status are measured at Cycle 2 Day1, Cycle 3 Day1, Cycle 4 Day1, Cycle 5 Day1 and Cycle 6 Day1. During follow period, 1 M after study drug therapy, then every 3 month up to 5 year (up to 60 months). Improvement is defined as a decrease from baseline by at least one step on the ECOG performance status scale (yes/no).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With no B-Symptoms or at Least One B-symptoms Over the Time</measure>
    <time_frame>Screening, Cycle1 Day 1, Cycle 2 Day1, Cycle 3 Day1, Cycle 4 Day1, Cycle 5 Day1, Cycle 6 Day 1 and During at 1M after study drug therapy, then every 3 M up to 5 year (up to 60 months)</time_frame>
    <description>Participants with no B-symptoms (B-Sy) (no night sweat, no weight loss, no fever and no extreme fatigue) and at least one indicated B-sy(night sweats, weight loss, fever or extreme fatigue) were presented at Screening, Cycle 1 Day 1, Cycle 2 Day1, Cycle 3 Day1, Cycle 4 Day1, Cycle 5 Day1, Cycle 6 Day 1 and during follow up period at 1 M after study drug therapy, then every 3 M up to 5 year (up to 60 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With the Best Overall Response (OR), as Assessed by the IRC</measure>
    <time_frame>From randomization up to 5 years after last dose of study drug</time_frame>
    <description>OR is defined as the number of participants achieving an objective response (complete response [CR], CR with incomplete bone marrow recovery [CRi], partial response [PR], and nodular PR [nPR]). CR (all the criteria at least 2 months after last treatment): no lymphadenopathy (Ly) &gt; 1.5 cm/ hepatomegaly/ splenomegaly/ constitutional symptoms; neutrophils &gt;1500 per microliter (µL), platelets (PL) &gt;100,000/µL, hemoglobin (Hb) &gt;11 grams/deciliter (g/dL), lymphocytes (LC) &lt;4000/µL, bone marrow (BM) sample must be normocellular for age, &lt;30% LC, no lymphoid nodule. CRi: CR criteria, persistent anemia/thrombocytopenia/neutropenia unrelated to CLL but related to drug toxicity. PR: &gt;=50% decrease in LC, Ly, size of liver and spleen and at least one of the following results: PL &gt;100,000/µL or 50% improvement over Baseline (BL), Hb &gt;11 g/dL or 50% improvement over BL. nPR: persistent nodules BM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With the Best OR, as Assessed by the Investigator</measure>
    <time_frame>From randomization up to 5 years after last dose of study drug</time_frame>
    <description>OR is defined as the number of participants achieving an objective response (complete response [CR], CR with incomplete bone marrow recovery [CRi], partial response [PR], and nodular PR [nPR]). CR (all the criteria at least 2 months after last treatment): no lymphadenopathy (Ly) &gt; 1.5 cm/ hepatomegaly/ splenomegaly/ constitutional symptoms; neutrophils &gt;1500 per microliter (µL), platelets (PL) &gt;100,000/µL, hemoglobin (Hb) &gt;11 grams/deciliter (g/dL), lymphocytes (LC) &lt;4000/µL, bone marrow (BM) sample must be normocellular for age, &lt;30% LC, no lymphoid nodule. CRi: CR criteria, persistent anemia/thrombocytopenia/neutropenia unrelated to CLL but related to drug toxicity. PR: &gt;=50% decrease in LC, Ly, size of liver and spleen and at least one of the following results: PL &gt;100,000/µL or 50% improvement over Baseline (BL), Hb &gt;11 g/dL or 50% improvement over BL. nPR: persistent nodules BM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Were Negative for Minimal Residual Disease (MRD) Assessed by IRC</measure>
    <time_frame>From randomization up to 5 years after last dose of study drug</time_frame>
    <description>MRD refers to small number of leukemic cells that remain in the participant during treatment or after treatment at the time the participant achieved a confirmed CR. MRD analysis was performed for the participants who were suspected of achieving a primary endpoint CR. MDR was performed by flow cytometry on a bone marrow or peripheral blood sample taken at least 2 months after final treatment. MRD negative was defined as less than one CLL cell per 10000 leukocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Were Negative for MRD Assessed by Investigator</measure>
    <time_frame>From randomization up to 5 years after last dose of study drug</time_frame>
    <description>MRD refers to small number of leukemic cells that remain in the participant during treatment or after treatment at the time the participant achieved a confirmed CR. MRD analysis was performed for the participants who were suspected of achieving a primary endpoint CR. MDR was performed by flow cytometry on a bone marrow or peripheral blood sample taken at least 2 months after final treatment. MRD negative was defined as less than one CLL cell per 10000 leukocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)</measure>
    <time_frame>From first dose of study medication to 60 Days after the last dose of study medication (for an AE), or up to 5 years after the last dose of study drug or until the time of the next anti-CLL therapy (for SAE)</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Human Anti-human Antibody (HAHA) Positive Result at Indicated Time Points</measure>
    <time_frame>From start of study drug until 60 days after the last dose of study medication</time_frame>
    <description>Serum samples for analysis of HAHA were collected at Baseline (Screening), after 3 cycles were compelted, after 1 M and 6 M post last dose. All samples were first tested in a screening step; positive samples from the screening were further evaluated in a confirmation test. The confirmed positive samples were reported as HAHA-positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Autoimmune Hemolytic Anaemia (AIHA)</measure>
    <time_frame>From first dose of study medication to 60 days after the last dose of study medication (for an AE), or up to 5 years after the last dose of study drug or until the time of the next anti-CLL therapy (for SAE)</time_frame>
    <description>AIHA is a condition where the body's immune system fails to recognize red blood cells as &quot;self&quot; and begins destroying these red blood cells. The number of participants experienced AIHA are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Drug Related AEs and SAEs of Maximum Severity of Grade 3 or Higher</measure>
    <time_frame>From first dose of study medication to 60 days after the last dose of study medication (for an AE), or up to 5 years after the last dose of study drug or until the time of the next anti-CLL therapy (for SAE)</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Maximum severity grades were evaluated according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0 (1, mild; 2, moderate; 3, severe; 4, life-threatening/disabling; 5, death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least One Grade 3/Grade 4 Myelosuppression (Anemia, Neutropenia, and Thrombocytopenia)</measure>
    <time_frame>From first dose of study medication to 60 days after the last dose of study medication (for an AE), or up to 5 years after the last dose of study drug or until the time of the next anti-CLL therapy (for SAE)</time_frame>
    <description>Participants with at least one Grade 3 or Grade 4 myelosuppression (anemia, neutropenia, and thrombocytopenia) are presented. Myelosuppression is defined as the decrease in the ability of the bone marrow to produce blood cells. AEs were graded according to NCI common terminology criteria for adverse events (CTCAE) grade, version 3.0 (1, mild; 2, moderate; 3, severe; 4, life-threatening/disabling; 5, death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Received no Transfusion or at Least One Transfusion During the Study</measure>
    <time_frame>From randomization up to 5 years after last dose of study drug</time_frame>
    <description>Participants who received no transfusion and at least one transfusion during the study are presented. Participants who took any blood products or blood supportive care product are included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Level of Immunoglobulin (Ig) Antibodies IgA, IgG, and IgM</measure>
    <time_frame>Baseline, 1M and 6M follow up</time_frame>
    <description>Immunoglobulins, or antibodies, are large proteins used by the immune system to identify and neutralize foreign particles such as bacteria and viruses. Their normal blood levels indicate proper immune status. Low levels indicate immuno-suppression. Blood samples were collected from each participant and IgA, IgG, and IgM were measured at Baseline, and 1M and 6M after last dose during follow up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cluster of Differentiation (CD) Cell Counts, CD5+ and CD19+</measure>
    <time_frame>Screening, Cycle 1 Day1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1 and after last dose at 1 M and then every three months up to 45 M during Follow-up Period</time_frame>
    <description>CD5+ and CD19+ cells were counted by flow cytometry at Screening (Baseline) on Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1 during the treatment period and after last dose of study drug at 1 M and then every three month follow up up to 45 M. Flow cytometry is a technique for counting and examining microscopic particles with an electronic detection apparatus. Baseline is defined as the assessment closest to but prior to first dose (e.g. day 1 if available, otherwise, screening). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cell Counts, CD5- CD19+</measure>
    <time_frame>Screening, Cycle 1 Day1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1 and after last dose at 1 M and then every three month up to 45 M during Follow-up Period</time_frame>
    <description>CD5- CD19+ cells were counted by flow cytometry at Screening (baseline) at Cycle 1 Day1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1 during treatment period and after last dose of study drug at 1 M and then every three month up to 45 M during follow up period. Flow cytometry is a technique for counting and examining microscopic particles with an electronic detection apparatus. Baseline is defined as the assessment closest to but prior to first dose (e.g. Day 1 if available otherwise screening). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic and Biological Markers Correlating With Clinical Response</measure>
    <time_frame>From randomization up to 5 years after last dose of study drug</time_frame>
    <description>Blood samples were collected for the assessment of the following prognostic markers at BL: immunoglobulin heavy chain variable region(IgVH) homology; Zeta-Chain-Associated Protein Kinase 70(ZAP70), VH3-21 usage; Cytogenetics (by fluorescent in situ hybridization [FISH]); beta 2 microglobulin. Cox-regression model was used to explore the relationship between progression-free survival and the following explanatory variables: treatment group, cytogenetics (analyzed by FISH included 6q-,11q-, +12q, 17p-, 13q-) , ZAP-70 (positive, negative or intermediate), VH3-21 usage (Yes and No), IgVH homology (&gt;98%, 97%-98% and &lt;97%), beta 2 microglobulin (&gt;3500 microgram per liter [µg/L] and &lt;=3500 µg/L). For each covariate, a hazard ratio &lt;1 indicates a lower risk on the first effect tested compared with the other effects tested. Cytogenetics Group (based on &gt;=20%)=cytogenetics (CY G).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Patient Reported Outcome (PRO) Measures and Scores for European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Chronic Lymphocytic Leukaemia 16 Item Module (EORTC QLQ-CLL 16)</measure>
    <time_frame>Screening, Cycle 3 Day 1, and 1 M and every 3 month post last dose up to 24 month.</time_frame>
    <description>The EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life (HRQoL) important in CLL. There are 4 multi-item scales - fatigue (2 items), treatment side effects ([TSE], 4 items), disease symptoms (disease effects scale [DES], 4 items), and infection scale [IS] (4 items) - and single item scales (social activities [Social Problems (SP) Scale] and future health worries[Future Health (FH) Scale].). These are measured on a four point scale where 1 = not at all and 4 = very much. These scores are transformed to give a rating from 0 - 100, where 0 =no symptoms or problems and 100 = a severe symptoms or problems. EORTC QLQ-CLL16 was assessed at Screening; Cycle 4 Day 1 and during follow-up 1 M and every 3 M up to 24 months. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value was obtained at randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Reported Outcome (PRO) as Assessed by EuroQoL Five-Dimension (EQ-5D) Score at Indicated Visit</measure>
    <time_frame>Screening, Cycle 3 Day 1, and 1 M and every 3 month post last dose up to 24 month.</time_frame>
    <description>EQ-5D is comprised of a 5-item health status measure and a visual analogue scale (VAS) and is used to generate two scores: the utility score and the thermometer score. The utility score measures mobility, self-care, usual activities, pain, discomfort, and anxiety/depression. Responses to each of the 5 health states are measured on a 3-point scale (level 1 = no problem; level 2 = some or moderate problem(s) and level 3 = unable, or extreme problems). Responses are typically converted into health utilities or valuations on a scale ranging from 0 (death) to 1 (perfect health). The thermometer score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A Negative health status describes health state worse than death.Baseline is the most recent, non-missing value prior to or on the first study drug dose date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Score</measure>
    <time_frame>Screening, Cycle 3 Day 1, and 1 M and every 3 month post last dose up to 24 month.</time_frame>
    <description>EORTC QLQ-C30, a self-reported, cancer-specific instrument assessing 15 domains: physical, role, emotional, cognitive and social functioning, pain,fatigue, nausea and vomiting, insomnia, loss of appetite, constipation, diarrhea, and dyspnea, financial difficulties and a global health status/quality of life (QOF). Functional and symptoms scales were measured on four point Likert scale where 1 = not at all and 4 = very much. Pat. assessed at Screening; Cycle 4 Day 1 and during follow-up 1 M and every 3 M up to 24 months. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Clinically meaningful changes or minimally important differences (MIDs)have been previously established for the EORTC QLQ C30, and categorized as 'small' if the mean change in scores is 5-10 points, 'moderate' if 10-20 points, and 'large' if &gt;20points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Health Change Questionnaire (HCQ)</measure>
    <time_frame>Screening, Cycle 3 Day 1, and 1 M and every 3 month post last dose up to 24 month.</time_frame>
    <description>The HCQ consists of a single question in which the participant is asked if he/she has experienced any change in his/her health overall since beginning the study. For HCQ, values from 1 to 9 were assigned to the 9 responses in the HCQ questionnaire, ranging from 1 for 'my health is a great deal better' to 9 for 'my health is a great deal worse' since the beginning of the study. Lower scores represent better conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Area Under the Time-concentration Curve (AUC) Curve Over the Dosing Interval (AUC[0-tau]) of Ofatumumab</measure>
    <time_frame>Cycle 1 Week 1, Cycle 1 Week 2, Cycles 2,3,4,5,6</time_frame>
    <description>Area under the time-concentration curve (AUC) over the dosing interval (AUC[0-tau]) was evaluated. Blood samples were collected from participants who received ofatumumab plus fludarabine and cyclophosphamide predose and 0.5 h after the end of the ofatumumab infusion at treatment Cycle 1 and Cycle 4 (Days 1, 8, and 85). In addition, predose samples were collected prior to ofatumumab administration at Cycles 2, 3, 5, and 6 (Days 29, 57, 113, and 141).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) and Observed Drug Concentration Prior to the Next Dose (Ctrough) of Ofatumumab</measure>
    <time_frame>Cycle 1 Week 1, Cycle 1 Week 2, Cycles 2,3,4,5</time_frame>
    <description>Blood samples were collected to assess the plasma concentration of ofatumumab.Cmax and Ctrough were determined. Blood samples were collected from participants who received ofatumumab plus fludarabine and cyclophosphamide predose and 0.5 h after the end of the ofatumumab infusion at treatment Cycle 1 and Cycle 4 (Days 1, 8, and 85). In addition, predose samples were collected prior to ofatumumab administration at Cycles 2, 3, 5, and 6 (Days 29, 57, 113, and 141).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Occurrence of Cmax (Tmax) of Ofatumumab</measure>
    <time_frame>Cycle 1 Week 1, Cycle 1 Week 2, Cycle 4</time_frame>
    <description>Blood samples were collected from participants who received ofatumumab plus fludarabine and cyclophosphamide predose and 0.5 h after the end of the ofatumumab infusion at treatment Cycle 1 and Cycle 4.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">365</enrollment>
  <condition>Leukaemia, Lymphocytic, Chronic</condition>
  <arm_group>
    <arm_group_label>Ofatumumab, Fludarabine, Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ofatumumab Cycle 1-Day 1 300mg, Cycle 1-Day 8 1000mg, then Cycles 2-6 Day 1 1000mg every 28 days, Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fludarabine, Cyclophosphamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OFC Infusion</intervention_name>
    <description>Ofatumumab Cycle 1-Day 1 300mg, Cycle 1-Day 8 1000mg, then Cycles 2-6 Day 1 1000mg every 28 days, Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles</description>
    <arm_group_label>Ofatumumab, Fludarabine, Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FC infusion</intervention_name>
    <description>Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250mg/m2 Days 1-3 every 28 days for 6 cycles</description>
    <arm_group_label>Fludarabine, Cyclophosphamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmed and active CLL requiring treatment

          -  at least one previous treatment for CLL and having achieved a complete or partial
             remission/response but after a period of 6 or more months, shows evidence of disease
             progression

          -  fully active at a minimum or fully capable of selfcare and up and about more than 50%
             of waking hours

          -  age 18yrs or older

          -  signed written informed consent

        Exclusion Criteria:

          -  diagnosis of refractory CLL (failure to achieve a complete or partial
             remission/response or disease progression within 6 months of last anti-CLL treatment

          -  abnormal/inadequate blood values, liver and kidney function

          -  certain heart problems, serious significant diseases, AIHA, other current cancers or
             within the last 5 years

          -  active or chronic infections

          -  use of drugs to suppress allergic or inflammatory responses (glucocorticoids)

          -  CLL transformation

          -  CLL central nervous system involvement

          -  current participation in other clinical study

          -  inability to comply with the protocol activities

          -  lactating or pregnant women or female patients of child-bearing potential (or male
             patients with such partners) not willing to use adequate contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-3833</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clinton</city>
        <state>Maryland</state>
        <zip>20735</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brasilia</city>
        <state>GoiÃ¡s</state>
        <zip>70390-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio De Janeiro</state>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20211-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20230 -130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21941-913</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>SÃ£o Paulo</city>
        <zip>03102-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>SÃ£o Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 3W4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Karlsruhe</city>
        <state>Baden-Wuerttemberg</state>
        <zip>76137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70190</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kassel</city>
        <state>Hessen</state>
        <zip>34119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lehrte</city>
        <state>Niedersachsen</state>
        <zip>31275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moenchengladbach-Rheydt</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saarbruecken</city>
        <state>Saarland</state>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22767</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens,</city>
        <zip>11 527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>564 29</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <zip>560029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mumbai</city>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mumbai</city>
        <zip>400014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pune</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vadodara</city>
        <zip>390007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Potenza</city>
        <state>Basilicata</state>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Albano Laziale (Roma)</city>
        <state>Lazio</state>
        <zip>00041</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ascoli Piceno</city>
        <state>Marche</state>
        <zip>63100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alessandria</city>
        <state>Piemonte</state>
        <zip>15100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novara</city>
        <state>Piemonte</state>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palermo</city>
        <state>Sicilia</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LeÃ³n</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LeÃ³n</state>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico City</city>
        <zip>CP 14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amersfoort</city>
        <zip>3818 ES</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Den Haag</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chorzow</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>93-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Opole</city>
        <zip>45-372</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Slupsk</city>
        <zip>76-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szczecin</city>
        <zip>71-242</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Iasi</city>
        <zip>700483</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300329</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>125101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St'Petersburg</city>
        <zip>191024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197 089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Badalona/Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cherkasy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Khmelnytskyi</city>
        <zip>29000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyiv</city>
        <zip>04112</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lviv</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Makiivka</city>
        <zip>86132</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Simferopil</city>
        <zip>95023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vinnitsa</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zhytomyr</city>
        <zip>10002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burton on Trent</city>
        <zip>DE13 0RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Carshalton</city>
        <zip>SM5 1AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cornwall</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cottingham</city>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dudley</city>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 OYN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Swindon</city>
        <zip>SN3 6BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uxbridge</city>
        <zip>UB8 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>India</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2009</study_first_submitted>
  <study_first_submitted_qc>January 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2009</study_first_posted>
  <results_first_submitted>August 10, 2015</results_first_submitted>
  <results_first_submitted_qc>June 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 25, 2016</results_first_posted>
  <last_update_submitted>December 13, 2017</last_update_submitted>
  <last_update_submitted_qc>December 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed</keyword>
  <keyword>Oncology</keyword>
  <keyword>Safety</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Ofatumumab</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Ofatumumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants (par) were screened within 14 days prior to the start of study drug administration to determine eligibility.</recruitment_details>
      <pre_assignment_details>Eligible par were stratified by Stage (Binet A vs. B vs. C) and number of prior therapies (1-2 vs. ≥3). Par in each stratum were then centrally randomized in a 1:1 ratio to recive intravenous (IV) fludarabine and cyclophosphamide in combination with ofatumumab or IV fludarabine and cyclophosphamide alone.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
          <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
        </group>
        <group group_id="P2">
          <title>Fludarabine + Cyclophosphamide</title>
          <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="182"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event,non-fatal</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
          <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
        </group>
        <group group_id="B2">
          <title>Fludarabine + Cyclophosphamide</title>
          <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="183"/>
            <count group_id="B2" value="182"/>
            <count group_id="B3" value="365"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.4" spread="8.82"/>
                    <measurement group_id="B2" value="61.6" spread="10.21"/>
                    <measurement group_id="B3" value="61.5" spread="9.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American/African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Central/South Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - South East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - Arabic/North African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS), as Assessed by the Independent Review Committee (IRC)</title>
        <description>PFS is defined as the interval of time between the date of randomization and the earlier of the date of disease progression (progressive disease,PD) and the date of death due to any cause. PD requires at least one of the following: lymphadenopathy, appearance of any new lesion such as enlargerd lymph nodes (&gt;1.5 cm) spleen or liver or other infiltrates or an increase by 50% or more in the greatest diameter of any previous site; an increase by 50% or more in the previously noted enlargement of the liver or spleen, an increase by 50% or more in the numbers of blood lymphocytes with at least 5000 lymphocytes per microliter, transformation to a more aggressive histology, or occurrence of cytopenia attributable to chronic lymphocytic leukaemia.</description>
        <time_frame>From randomization up to 5 years after last dose of study drug</time_frame>
        <population>Intent-to-Treat (ITT) Population: all participants randomized and received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS), as Assessed by the Independent Review Committee (IRC)</title>
          <description>PFS is defined as the interval of time between the date of randomization and the earlier of the date of disease progression (progressive disease,PD) and the date of death due to any cause. PD requires at least one of the following: lymphadenopathy, appearance of any new lesion such as enlargerd lymph nodes (&gt;1.5 cm) spleen or liver or other infiltrates or an increase by 50% or more in the greatest diameter of any previous site; an increase by 50% or more in the previously noted enlargement of the liver or spleen, an increase by 50% or more in the numbers of blood lymphocytes with at least 5000 lymphocytes per microliter, transformation to a more aggressive histology, or occurrence of cytopenia attributable to chronic lymphocytic leukaemia.</description>
          <population>Intent-to-Treat (ITT) Population: all participants randomized and received study drug.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.94" lower_limit="22.80" upper_limit="35.88"/>
                    <measurement group_id="O2" value="18.83" lower_limit="14.42" upper_limit="25.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0032</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival is defined as the time from randomization to death due to any cause. Each participant was followed at the time when the last IRC-assessed PFS events occurred. Participants who had not died were censored at the date of last contact.</description>
        <time_frame>From randomization up to 5 years after last dose of study drug</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival is defined as the time from randomization to death due to any cause. Each participant was followed at the time when the last IRC-assessed PFS events occurred. Participants who had not died were censored at the date of last contact.</description>
          <population>ITT Population.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.38" lower_limit="44.16">Upper limit was not able to calucualted due to an insufficient number of events (high censoring rate) and high follow-up time.</measurement>
                    <measurement group_id="O2" value="45.77" lower_limit="37.26">Upper limit was not able to calucualted due to an insufficient number of events (high censoring rate) and high follow-up time.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1410</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response, as Assessed by the IRC</title>
        <description>Time to response is defined as the time from randomization to the first response. Complete Response/remission(CR) all the criteria at least 2 months after last treatment: no lymphadenopathy(Ly) &gt; 1.5 cm/ hepatomegaly/spleenomegaly/constitutional symptoms; neutrophils &gt;1500 per microliter(µL), platelets(PL) &gt;100,000/µL, hemoglobin(Hb) &gt;11 grams/deciliter(g/dL), lymphocytes(LC) &lt;4000/µL, bone marrow(BM) sample must be normocellular for age, &lt;30% LC, no lymphoid nodule. Incomplete bone marrow recovery(CRi): CR criteria, persistent anemia/thrombocytopenia/neutropenia unrelated to CLL but related to drug toxicity. Partial Remission/response(PR): &gt;=50% decrease in LC, Ly, size of liver and spleen and at least one of the following results: PL &gt;100,000/µL or 50% improvement over Baseline(BL), Hb &gt;11 g/dL or 50% improvement over BL. Nodular PR(nPR): persistent nodules BM.</description>
        <time_frame>From randomization up to 5 years after last dose of study drug</time_frame>
        <population>ITT Population. Participants with unknown or missing responses were considered as non-responders. Only responders were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response, as Assessed by the IRC</title>
          <description>Time to response is defined as the time from randomization to the first response. Complete Response/remission(CR) all the criteria at least 2 months after last treatment: no lymphadenopathy(Ly) &gt; 1.5 cm/ hepatomegaly/spleenomegaly/constitutional symptoms; neutrophils &gt;1500 per microliter(µL), platelets(PL) &gt;100,000/µL, hemoglobin(Hb) &gt;11 grams/deciliter(g/dL), lymphocytes(LC) &lt;4000/µL, bone marrow(BM) sample must be normocellular for age, &lt;30% LC, no lymphoid nodule. Incomplete bone marrow recovery(CRi): CR criteria, persistent anemia/thrombocytopenia/neutropenia unrelated to CLL but related to drug toxicity. Partial Remission/response(PR): &gt;=50% decrease in LC, Ly, size of liver and spleen and at least one of the following results: PL &gt;100,000/µL or 50% improvement over Baseline(BL), Hb &gt;11 g/dL or 50% improvement over BL. Nodular PR(nPR): persistent nodules BM.</description>
          <population>ITT Population. Participants with unknown or missing responses were considered as non-responders. Only responders were included in the analysis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.95" upper_limit="1.08"/>
                    <measurement group_id="O2" value="0.99" lower_limit="0.95" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4490</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR), as Assessed by the IRC</title>
        <description>DOR is defined as the time from the initial response (CR, CRi, nPR, or PR) to the first documented sign of PD or death due to any cause. PD requires at least one of the following: lymphadenopathy, appearance of any new lesion such as enlargerd lymph nodes (&gt;1.5 cm) spleen or liver or other infiltrates or an increase by 50% or more in the greatest diameter of any previous site; an increase by 50% or more in the previously noted enlargement of the liver or spleen, an increase by 50% or more in the numbers of blood lymphocytes with at least 5000 lymphocytes per microliter, transformation to a more aggressive histology, or occurrence of cytopenia attributable to chronic lymphocytic leukaemia.</description>
        <time_frame>From time of initial response to disease progression or death, whichever came first (up to 5 years after the last dose of study drug)</time_frame>
        <population>ITT Population. Par with unknown or missing responses were considered as non-responders, only responders were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR), as Assessed by the IRC</title>
          <description>DOR is defined as the time from the initial response (CR, CRi, nPR, or PR) to the first documented sign of PD or death due to any cause. PD requires at least one of the following: lymphadenopathy, appearance of any new lesion such as enlargerd lymph nodes (&gt;1.5 cm) spleen or liver or other infiltrates or an increase by 50% or more in the greatest diameter of any previous site; an increase by 50% or more in the previously noted enlargement of the liver or spleen, an increase by 50% or more in the numbers of blood lymphocytes with at least 5000 lymphocytes per microliter, transformation to a more aggressive histology, or occurrence of cytopenia attributable to chronic lymphocytic leukaemia.</description>
          <population>ITT Population. Par with unknown or missing responses were considered as non-responders, only responders were included in this analysis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.63" lower_limit="25.03" upper_limit="41.46"/>
                    <measurement group_id="O2" value="24.90" lower_limit="18.99" upper_limit="28.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0878</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression, as Assessed by the IRC</title>
        <description>Time to progression is defined as the time from the date of randomization to PD. PD requires at least one of the following: lymphadenopathy, appearance of any new lesion such as enlargerd lymph nodes (&gt;1.5 cm) spleen or liver or other infiltrates or an increase by 50% or more in the greatest diameter of any previous site; an increase by 50% or more in the previously noted enlargement of the liver or spleen, an increase by 50% or more in the numbers of blood lymphocytes with at least 5000 lymphocytes per microliter, transformation to a more aggressive histology, or occurrence of cytopenia attributable to chronic lymphocytic leukaemia.</description>
        <time_frame>From randomization up to 5 years after the last dose of study drug</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression, as Assessed by the IRC</title>
          <description>Time to progression is defined as the time from the date of randomization to PD. PD requires at least one of the following: lymphadenopathy, appearance of any new lesion such as enlargerd lymph nodes (&gt;1.5 cm) spleen or liver or other infiltrates or an increase by 50% or more in the greatest diameter of any previous site; an increase by 50% or more in the previously noted enlargement of the liver or spleen, an increase by 50% or more in the numbers of blood lymphocytes with at least 5000 lymphocytes per microliter, transformation to a more aggressive histology, or occurrence of cytopenia attributable to chronic lymphocytic leukaemia.</description>
          <population>ITT Population.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.12" lower_limit="28.94" upper_limit="47.67"/>
                    <measurement group_id="O2" value="26.78" lower_limit="22.51" upper_limit="31.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0036</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Next Therapy</title>
        <description>Time to next therapy is defined as the time from randomization until the start of the next-line of treatment.</description>
        <time_frame>From the start of study drug until the start of the next anti-CLL therapy (up to 5 years after the last dose of study drug)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Next Therapy</title>
          <description>Time to next therapy is defined as the time from randomization until the start of the next-line of treatment.</description>
          <population>ITT Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.13" lower_limit="40.54" upper_limit="60.39"/>
                    <measurement group_id="O2" value="40.08" lower_limit="32.07" upper_limit="48.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0735</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Improvement in Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
        <description>The ECOG performance status scales and criteria are used by doctors and researchers to assess how a participant's disease is progressing, how the disease affects the daily living, and determines appropriate treatment and prognosis. ECOG performance status are measured at Cycle 2 Day1, Cycle 3 Day1, Cycle 4 Day1, Cycle 5 Day1 and Cycle 6 Day1. During follow period, 1 M after study drug therapy, then every 3 month up to 5 year (up to 60 months). Improvement is defined as a decrease from baseline by at least one step on the ECOG performance status scale (yes/no).</description>
        <time_frame>Cycle 2 Day1, Cycle 3 Day1, Cycle 4 Day1, Cycle 5 Day1, Cycle 6 Day1, follow up (FU) at 1Month (M) after study drug therapy, then every 3 month up to 5 year (up to 60 months)</time_frame>
        <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement in Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
          <description>The ECOG performance status scales and criteria are used by doctors and researchers to assess how a participant's disease is progressing, how the disease affects the daily living, and determines appropriate treatment and prognosis. ECOG performance status are measured at Cycle 2 Day1, Cycle 3 Day1, Cycle 4 Day1, Cycle 5 Day1 and Cycle 6 Day1. During follow period, 1 M after study drug therapy, then every 3 month up to 5 year (up to 60 months). Improvement is defined as a decrease from baseline by at least one step on the ECOG performance status scale (yes/no).</description>
          <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 2 Day 1, n= 170, 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1, n= 165,157</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1, n= 153, 132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1, n= 135, 118</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1, n= 120, 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M, FU, n= 159, 145</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 M, FU, n= 152, 119</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 M, FU, n= 136, 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 M, FU, n= 127, 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 M, FU, n= 118, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 M, FU, n= 102, 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 M, FU, n= 96 ,65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 M, FU, n= 92, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 M, FU, n= 80, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>27 M, FU, n= 73, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 M, FU, n= 67, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>33 M, FU, n= 55, 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 M, FU, n= 44, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>39 M, FU, n= 30, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>42 M, FU, n= 21, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 M, FU, n= 15, 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 M, FU, n= 11, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>51 M, FU, n= 10, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54 M, FU, n= 8, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>57 M, FU, n= 4, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed at this time point therefore there is no data to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 M, FU, n= 3, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed at this time point therefore there is no data to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With no B-Symptoms or at Least One B-symptoms Over the Time</title>
        <description>Participants with no B-symptoms (B-Sy) (no night sweat, no weight loss, no fever and no extreme fatigue) and at least one indicated B-sy(night sweats, weight loss, fever or extreme fatigue) were presented at Screening, Cycle 1 Day 1, Cycle 2 Day1, Cycle 3 Day1, Cycle 4 Day1, Cycle 5 Day1, Cycle 6 Day 1 and during follow up period at 1 M after study drug therapy, then every 3 M up to 5 year (up to 60 months).</description>
        <time_frame>Screening, Cycle1 Day 1, Cycle 2 Day1, Cycle 3 Day1, Cycle 4 Day1, Cycle 5 Day1, Cycle 6 Day 1 and During at 1M after study drug therapy, then every 3 M up to 5 year (up to 60 months)</time_frame>
        <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With no B-Symptoms or at Least One B-symptoms Over the Time</title>
          <description>Participants with no B-symptoms (B-Sy) (no night sweat, no weight loss, no fever and no extreme fatigue) and at least one indicated B-sy(night sweats, weight loss, fever or extreme fatigue) were presented at Screening, Cycle 1 Day 1, Cycle 2 Day1, Cycle 3 Day1, Cycle 4 Day1, Cycle 5 Day1, Cycle 6 Day 1 and during follow up period at 1 M after study drug therapy, then every 3 M up to 5 year (up to 60 months).</description>
          <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening, no B-sy, n= 183, 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening, one B-sy, n= 183, 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1, no B-sy, n= 179, 179</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1, one B-sy, n= 179, 179</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1,no B-sy, n= 168, 170</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1, one B-sy, n= 168, 170</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1, no B-sy, n= 165, 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1, one B-sy, n= 165, 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1, no B-sy, n= 154, 132,</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1, one B-sy, n= 154, 132,</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1, no B-sy, n= 134, 118</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1, one B-sy, n= 134, 118</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1, no B-sy, n= 120, 95</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1, one B-sy, n= 120, 95</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M, FU, no B-sy, n= 161, 145</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M, FU, one B-sy, n= 161, 145</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 M, FU, no B-sy, n= 153, 119</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 M, FU, one B-sy, n= 153, 119</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 M, FU, no B-sy, n= 138, 107</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 M, FU, one B-sy, n= 138, 107</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 M, FU, no B-sy, n= 129, 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 M, FU, one B-sy, n= 129, 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 M, FU, no B-sy, n= 119, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 M, FU, one B-sy, n= 119, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 M, FU, no B-sy, n= 103, 71</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 M, FU, one B-sy, n= 103, 71</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 M, FU, no B-sy, n= 98, 65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 M, FU, one B-sy, n= 98, 65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 M, FU, no B-sy, n= 94, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 M, FU, one B-sy , n= 94, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 M, FU, no B-sy, n= 80, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 M, FU, one B-sy, n= 80, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>27 M, FU, no B-sy, n= 74, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>27 M, FU, one B-syn, n= 74, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 M, FU, no B-sy, n= 68, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 M, FU, one B-sy, n= 68, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>33 M, FU, no B-sy, n= 55, 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>33 M, FU, one B-sy, n= 55, 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 M, FU, no B-sy, n=44, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 M, FU, one B-sy, n=44, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>39 M, FU, no B-sy, n=31, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>39 M, FU, one B-sy, n=31, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>42 M, FU, no B-sy, n=22, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>42 M, FU, one B-sy, n=22, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 M, FU, no B-sy, n=n=17, 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 M, FU, one B-sy, n=17, 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 M, FU, no B-sy, n=11, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 M, FU, one B-sy, n=11, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>51 M, FU, no B-sy, n=10, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>51 M, FU, one B-sy, n=10, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54 M, FU, no B-sy, n=8, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54 M, FU, one B-sy, n=8, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>57 M, FU, no B-sy, n=4, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed at this time point therefore there is no data to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>57 M, FU, one B-sy, n=4, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed at this time point therefore there is no data to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 M, FU, no B-sy, n=3, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed at this time point therefore there is no data to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 M, FU, one B-sy, n=3, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed at this time point therefore there is no data to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With the Best Overall Response (OR), as Assessed by the IRC</title>
        <description>OR is defined as the number of participants achieving an objective response (complete response [CR], CR with incomplete bone marrow recovery [CRi], partial response [PR], and nodular PR [nPR]). CR (all the criteria at least 2 months after last treatment): no lymphadenopathy (Ly) &gt; 1.5 cm/ hepatomegaly/ splenomegaly/ constitutional symptoms; neutrophils &gt;1500 per microliter (µL), platelets (PL) &gt;100,000/µL, hemoglobin (Hb) &gt;11 grams/deciliter (g/dL), lymphocytes (LC) &lt;4000/µL, bone marrow (BM) sample must be normocellular for age, &lt;30% LC, no lymphoid nodule. CRi: CR criteria, persistent anemia/thrombocytopenia/neutropenia unrelated to CLL but related to drug toxicity. PR: &gt;=50% decrease in LC, Ly, size of liver and spleen and at least one of the following results: PL &gt;100,000/µL or 50% improvement over Baseline (BL), Hb &gt;11 g/dL or 50% improvement over BL. nPR: persistent nodules BM.</description>
        <time_frame>From randomization up to 5 years after last dose of study drug</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With the Best Overall Response (OR), as Assessed by the IRC</title>
          <description>OR is defined as the number of participants achieving an objective response (complete response [CR], CR with incomplete bone marrow recovery [CRi], partial response [PR], and nodular PR [nPR]). CR (all the criteria at least 2 months after last treatment): no lymphadenopathy (Ly) &gt; 1.5 cm/ hepatomegaly/ splenomegaly/ constitutional symptoms; neutrophils &gt;1500 per microliter (µL), platelets (PL) &gt;100,000/µL, hemoglobin (Hb) &gt;11 grams/deciliter (g/dL), lymphocytes (LC) &lt;4000/µL, bone marrow (BM) sample must be normocellular for age, &lt;30% LC, no lymphoid nodule. CRi: CR criteria, persistent anemia/thrombocytopenia/neutropenia unrelated to CLL but related to drug toxicity. PR: &gt;=50% decrease in LC, Ly, size of liver and spleen and at least one of the following results: PL &gt;100,000/µL or 50% improvement over Baseline (BL), Hb &gt;11 g/dL or 50% improvement over BL. nPR: persistent nodules BM.</description>
          <population>ITT Population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nPR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With the Best OR, as Assessed by the Investigator</title>
        <description>OR is defined as the number of participants achieving an objective response (complete response [CR], CR with incomplete bone marrow recovery [CRi], partial response [PR], and nodular PR [nPR]). CR (all the criteria at least 2 months after last treatment): no lymphadenopathy (Ly) &gt; 1.5 cm/ hepatomegaly/ splenomegaly/ constitutional symptoms; neutrophils &gt;1500 per microliter (µL), platelets (PL) &gt;100,000/µL, hemoglobin (Hb) &gt;11 grams/deciliter (g/dL), lymphocytes (LC) &lt;4000/µL, bone marrow (BM) sample must be normocellular for age, &lt;30% LC, no lymphoid nodule. CRi: CR criteria, persistent anemia/thrombocytopenia/neutropenia unrelated to CLL but related to drug toxicity. PR: &gt;=50% decrease in LC, Ly, size of liver and spleen and at least one of the following results: PL &gt;100,000/µL or 50% improvement over Baseline (BL), Hb &gt;11 g/dL or 50% improvement over BL. nPR: persistent nodules BM.</description>
        <time_frame>From randomization up to 5 years after last dose of study drug</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With the Best OR, as Assessed by the Investigator</title>
          <description>OR is defined as the number of participants achieving an objective response (complete response [CR], CR with incomplete bone marrow recovery [CRi], partial response [PR], and nodular PR [nPR]). CR (all the criteria at least 2 months after last treatment): no lymphadenopathy (Ly) &gt; 1.5 cm/ hepatomegaly/ splenomegaly/ constitutional symptoms; neutrophils &gt;1500 per microliter (µL), platelets (PL) &gt;100,000/µL, hemoglobin (Hb) &gt;11 grams/deciliter (g/dL), lymphocytes (LC) &lt;4000/µL, bone marrow (BM) sample must be normocellular for age, &lt;30% LC, no lymphoid nodule. CRi: CR criteria, persistent anemia/thrombocytopenia/neutropenia unrelated to CLL but related to drug toxicity. PR: &gt;=50% decrease in LC, Ly, size of liver and spleen and at least one of the following results: PL &gt;100,000/µL or 50% improvement over Baseline (BL), Hb &gt;11 g/dL or 50% improvement over BL. nPR: persistent nodules BM.</description>
          <population>ITT Population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nPR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0166</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Were Negative for Minimal Residual Disease (MRD) Assessed by IRC</title>
        <description>MRD refers to small number of leukemic cells that remain in the participant during treatment or after treatment at the time the participant achieved a confirmed CR. MRD analysis was performed for the participants who were suspected of achieving a primary endpoint CR. MDR was performed by flow cytometry on a bone marrow or peripheral blood sample taken at least 2 months after final treatment. MRD negative was defined as less than one CLL cell per 10000 leukocytes.</description>
        <time_frame>From randomization up to 5 years after last dose of study drug</time_frame>
        <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Negative for Minimal Residual Disease (MRD) Assessed by IRC</title>
          <description>MRD refers to small number of leukemic cells that remain in the participant during treatment or after treatment at the time the participant achieved a confirmed CR. MRD analysis was performed for the participants who were suspected of achieving a primary endpoint CR. MDR was performed by flow cytometry on a bone marrow or peripheral blood sample taken at least 2 months after final treatment. MRD negative was defined as less than one CLL cell per 10000 leukocytes.</description>
          <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening, n= 46, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1, n= 2, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed at this time point therefore there is no data to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 M, FU, n= 44, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 M, FU, n= 35, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 M, FU, n= 29, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 M, FU, n= 25, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 M, FU, n= 20, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 M, FU, n= 16, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 M, FU, n= 13, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 M, FU, n= 9, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>27 M, FU, n= 9, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 M, FU, n= 9, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>33 M, FU, n= 5, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 M, FU, n= 5, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>39 M, FU, n= 2, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>42 M, FU, n= 2, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed at this time point therefore there is no data to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 M, FU, n= 1, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 M, FU, n= 2, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>51 M, FU, n= 2, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54 M, FU, n= 2, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Were Negative for MRD Assessed by Investigator</title>
        <description>MRD refers to small number of leukemic cells that remain in the participant during treatment or after treatment at the time the participant achieved a confirmed CR. MRD analysis was performed for the participants who were suspected of achieving a primary endpoint CR. MDR was performed by flow cytometry on a bone marrow or peripheral blood sample taken at least 2 months after final treatment. MRD negative was defined as less than one CLL cell per 10000 leukocytes.</description>
        <time_frame>From randomization up to 5 years after last dose of study drug</time_frame>
        <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Negative for MRD Assessed by Investigator</title>
          <description>MRD refers to small number of leukemic cells that remain in the participant during treatment or after treatment at the time the participant achieved a confirmed CR. MRD analysis was performed for the participants who were suspected of achieving a primary endpoint CR. MDR was performed by flow cytometry on a bone marrow or peripheral blood sample taken at least 2 months after final treatment. MRD negative was defined as less than one CLL cell per 10000 leukocytes.</description>
          <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening, n= 39, 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1, n= 2, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed at this time point therefore there is no data to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 M, FU, n= 34, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 M, FU, n= 26, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 M, FU, n= 24, 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 M, FU, n= 18, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 M, FU, n= 17, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 M, FU, n= 12, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 M, FU, n= 11, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 M, FU, n= 6, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>27 M, FU, n= 7, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 M, FU, n= 7, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>33 M, FU, n= 5, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 M, FU, n= 5, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>39 M, FU, n= 4, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>42 M, FU, n= 4, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed at this time point therefore there is no data to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 M, FU, n= 2, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed at this time point therefore there is no data to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 M, FU, n= 3, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed at this time point therefore there is no data to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>51 M, FU, n= 2, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed at this time point therefore there is no data to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>54 M, FU, n= 2, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed at this time point therefore there is no data to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)</title>
        <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury.</description>
        <time_frame>From first dose of study medication to 60 Days after the last dose of study medication (for an AE), or up to 5 years after the last dose of study drug or until the time of the next anti-CLL therapy (for SAE)</time_frame>
        <population>Safety Population: Participants who received at least one dose of a study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)</title>
          <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury.</description>
          <population>Safety Population: Participants who received at least one dose of a study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Human Anti-human Antibody (HAHA) Positive Result at Indicated Time Points</title>
        <description>Serum samples for analysis of HAHA were collected at Baseline (Screening), after 3 cycles were compelted, after 1 M and 6 M post last dose. All samples were first tested in a screening step; positive samples from the screening were further evaluated in a confirmation test. The confirmed positive samples were reported as HAHA-positive.</description>
        <time_frame>From start of study drug until 60 days after the last dose of study medication</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles)</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Human Anti-human Antibody (HAHA) Positive Result at Indicated Time Points</title>
          <description>Serum samples for analysis of HAHA were collected at Baseline (Screening), after 3 cycles were compelted, after 1 M and 6 M post last dose. All samples were first tested in a screening step; positive samples from the screening were further evaluated in a confirmation test. The confirmed positive samples were reported as HAHA-positive.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening Visit, n= 179,177</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1, n= 151,130</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M, FU, n= 148,132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 M, FU, n= 0,1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed at this time point therefore there is no data to present.</measurement>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 M, FU, n= 130, 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 M, FU, n= 0, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed at this time point therefore there is no data to present.</measurement>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 M, FU, n= 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed at this time point therefore there is no data to present.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed at this time point therefore there is no data to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Autoimmune Hemolytic Anaemia (AIHA)</title>
        <description>AIHA is a condition where the body's immune system fails to recognize red blood cells as &quot;self&quot; and begins destroying these red blood cells. The number of participants experienced AIHA are presented.</description>
        <time_frame>From first dose of study medication to 60 days after the last dose of study medication (for an AE), or up to 5 years after the last dose of study drug or until the time of the next anti-CLL therapy (for SAE)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Autoimmune Hemolytic Anaemia (AIHA)</title>
          <description>AIHA is a condition where the body's immune system fails to recognize red blood cells as &quot;self&quot; and begins destroying these red blood cells. The number of participants experienced AIHA are presented.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Drug Related AEs and SAEs of Maximum Severity of Grade 3 or Higher</title>
        <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Maximum severity grades were evaluated according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0 (1, mild; 2, moderate; 3, severe; 4, life-threatening/disabling; 5, death).</description>
        <time_frame>From first dose of study medication to 60 days after the last dose of study medication (for an AE), or up to 5 years after the last dose of study drug or until the time of the next anti-CLL therapy (for SAE)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Drug Related AEs and SAEs of Maximum Severity of Grade 3 or Higher</title>
          <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Maximum severity grades were evaluated according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0 (1, mild; 2, moderate; 3, severe; 4, life-threatening/disabling; 5, death).</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With at Least One Grade 3/Grade 4 Myelosuppression (Anemia, Neutropenia, and Thrombocytopenia)</title>
        <description>Participants with at least one Grade 3 or Grade 4 myelosuppression (anemia, neutropenia, and thrombocytopenia) are presented. Myelosuppression is defined as the decrease in the ability of the bone marrow to produce blood cells. AEs were graded according to NCI common terminology criteria for adverse events (CTCAE) grade, version 3.0 (1, mild; 2, moderate; 3, severe; 4, life-threatening/disabling; 5, death).</description>
        <time_frame>From first dose of study medication to 60 days after the last dose of study medication (for an AE), or up to 5 years after the last dose of study drug or until the time of the next anti-CLL therapy (for SAE)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Grade 3/Grade 4 Myelosuppression (Anemia, Neutropenia, and Thrombocytopenia)</title>
          <description>Participants with at least one Grade 3 or Grade 4 myelosuppression (anemia, neutropenia, and thrombocytopenia) are presented. Myelosuppression is defined as the decrease in the ability of the bone marrow to produce blood cells. AEs were graded according to NCI common terminology criteria for adverse events (CTCAE) grade, version 3.0 (1, mild; 2, moderate; 3, severe; 4, life-threatening/disabling; 5, death).</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Received no Transfusion or at Least One Transfusion During the Study</title>
        <description>Participants who received no transfusion and at least one transfusion during the study are presented. Participants who took any blood products or blood supportive care product are included.</description>
        <time_frame>From randomization up to 5 years after last dose of study drug</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Received no Transfusion or at Least One Transfusion During the Study</title>
          <description>Participants who received no transfusion and at least one transfusion during the study are presented. Participants who took any blood products or blood supportive care product are included.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one transfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No transfusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Level of Immunoglobulin (Ig) Antibodies IgA, IgG, and IgM</title>
        <description>Immunoglobulins, or antibodies, are large proteins used by the immune system to identify and neutralize foreign particles such as bacteria and viruses. Their normal blood levels indicate proper immune status. Low levels indicate immuno-suppression. Blood samples were collected from each participant and IgA, IgG, and IgM were measured at Baseline, and 1M and 6M after last dose during follow up period.</description>
        <time_frame>Baseline, 1M and 6M follow up</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Level of Immunoglobulin (Ig) Antibodies IgA, IgG, and IgM</title>
          <description>Immunoglobulins, or antibodies, are large proteins used by the immune system to identify and neutralize foreign particles such as bacteria and viruses. Their normal blood levels indicate proper immune status. Low levels indicate immuno-suppression. Blood samples were collected from each participant and IgA, IgG, and IgM were measured at Baseline, and 1M and 6M after last dose during follow up period.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</population>
          <units>Gram per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 1, IgA, n= 179, 175</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.74"/>
                    <measurement group_id="O2" value="0.9" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1, IgG, n= 179, 175</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="5.22"/>
                    <measurement group_id="O2" value="8.2" spread="3.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1, IgM, FU, n= 179, 175</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.36"/>
                    <measurement group_id="O2" value="0.8" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M, FU, IgA, n= 150, 131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.79"/>
                    <measurement group_id="O2" value="1.0" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M, FU, IgG, n= 150, 131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="4.05"/>
                    <measurement group_id="O2" value="7.9" spread="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M, FU, IgM, FU, n= 150, 131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.16"/>
                    <measurement group_id="O2" value="0.8" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 M, FU, IgA, n= 130, 101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.77"/>
                    <measurement group_id="O2" value="1.0" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 M, FU, IgG, n= 130, 101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="3.97"/>
                    <measurement group_id="O2" value="8.9" spread="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 M, FU, IgM, FU, n= 130, 101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.50"/>
                    <measurement group_id="O2" value="1.1" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cluster of Differentiation (CD) Cell Counts, CD5+ and CD19+</title>
        <description>CD5+ and CD19+ cells were counted by flow cytometry at Screening (Baseline) on Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1 during the treatment period and after last dose of study drug at 1 M and then every three month follow up up to 45 M. Flow cytometry is a technique for counting and examining microscopic particles with an electronic detection apparatus. Baseline is defined as the assessment closest to but prior to first dose (e.g. day 1 if available, otherwise, screening). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
        <time_frame>Screening, Cycle 1 Day1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1 and after last dose at 1 M and then every three months up to 45 M during Follow-up Period</time_frame>
        <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cluster of Differentiation (CD) Cell Counts, CD5+ and CD19+</title>
          <description>CD5+ and CD19+ cells were counted by flow cytometry at Screening (Baseline) on Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1 during the treatment period and after last dose of study drug at 1 M and then every three month follow up up to 45 M. Flow cytometry is a technique for counting and examining microscopic particles with an electronic detection apparatus. Baseline is defined as the assessment closest to but prior to first dose (e.g. day 1 if available, otherwise, screening). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
          <population>ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</population>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 1,n=1, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31831.0">No standard deviation was able to be calculated for this data point because only one participant was analyzed.</measurement>
                    <measurement group_id="O2" value="0.0">No standard deviation was able to be calculated for this data point because only one participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 15, n=58, 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48264.8" spread="53938.54"/>
                    <measurement group_id="O2" value="-45765.3" spread="74000.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1,n=56, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47014.6" spread="55671.72"/>
                    <measurement group_id="O2" value="-46741.3" spread="69968.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 15,n=56, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51097.6" spread="55716.26"/>
                    <measurement group_id="O2" value="-51798.6" spread="76481.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1,n=56, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48620.6" spread="52125.67"/>
                    <measurement group_id="O2" value="-52271.6" spread="72241.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1,n=50, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48371.5" spread="52861.69"/>
                    <measurement group_id="O2" value="-44214.9" spread="48479.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1,n=48, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45449.3" spread="53029.66"/>
                    <measurement group_id="O2" value="-57907.9" spread="84532.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1,n=46, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46663.3" spread="53764.88"/>
                    <measurement group_id="O2" value="-57768.4" spread="88365.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M, FU, n=53, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52594.2" spread="57724.72"/>
                    <measurement group_id="O2" value="-51620.8" spread="75958.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 M, FU, n=58, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49715.4" spread="56620.15"/>
                    <measurement group_id="O2" value="-43600.1" spread="50794.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 M, FU, n=49, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46206.3" spread="55950.85"/>
                    <measurement group_id="O2" value="-42362.7" spread="52253.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 M, FU, n=44, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48312.5" spread="55804.80"/>
                    <measurement group_id="O2" value="-44165.1" spread="53748.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 M, FU, n=36, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39263.4" spread="45697.94"/>
                    <measurement group_id="O2" value="-46579.8" spread="59571.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 M, FU, n=27, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36304.9" spread="42409.61"/>
                    <measurement group_id="O2" value="-53308.2" spread="70701.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 M, FU, n=17, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31236.4" spread="28885.37"/>
                    <measurement group_id="O2" value="-58586.1" spread="81081.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 M, FU, n=17, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22429.8" spread="22228.60"/>
                    <measurement group_id="O2" value="-52206.9" spread="84922.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 M, FU, n=6, 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31970.3" spread="22821.08"/>
                    <measurement group_id="O2" value="-58815.0" spread="99596.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>27 M, FU, n=4, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33897.0" spread="21892.29"/>
                    <measurement group_id="O2" value="-84811.0" spread="118231.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 M, FU, n=4, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18168.0" spread="16865.29"/>
                    <measurement group_id="O2" value="-436.0">No standard deviation was able to be calculated for this data point because only one participant was analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>33 M, FU, n=2, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23940.5" spread="23671.81"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed for this time point therefore there is no data point to present</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 M, FU, n=2, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20802.0" spread="27917.99"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed for this time point therefore there is no data point to present</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>39 M, FU, n=1, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40237.0">No standard deviation was able to be calculated for this data point because only one participant was analyzed.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed for this time point therefore there is no data point to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>42 M, FU, n=1, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39154.0">No standard deviation was able to be calculated for this data point because only one participant was analyzed.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed for this time point therefore there is no data point to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 M, FU, n=1, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35049.0">No standard deviation was able to be calculated for this data point because only one participant was analyzed.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed for this time point therefore there is no data point to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cell Counts, CD5- CD19+</title>
        <description>CD5- CD19+ cells were counted by flow cytometry at Screening (baseline) at Cycle 1 Day1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1 during treatment period and after last dose of study drug at 1 M and then every three month up to 45 M during follow up period. Flow cytometry is a technique for counting and examining microscopic particles with an electronic detection apparatus. Baseline is defined as the assessment closest to but prior to first dose (e.g. Day 1 if available otherwise screening). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
        <time_frame>Screening, Cycle 1 Day1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1 and after last dose at 1 M and then every three month up to 45 M during Follow-up Period</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cell Counts, CD5- CD19+</title>
          <description>CD5- CD19+ cells were counted by flow cytometry at Screening (baseline) at Cycle 1 Day1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1 during treatment period and after last dose of study drug at 1 M and then every three month up to 45 M during follow up period. Flow cytometry is a technique for counting and examining microscopic particles with an electronic detection apparatus. Baseline is defined as the assessment closest to but prior to first dose (e.g. Day 1 if available otherwise screening). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
          <population>Safety Population</population>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening, n=61,54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5228.6" spread="22503.30"/>
                    <measurement group_id="O2" value="7865.6" spread="42925.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1,n=60, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6646.1" spread="24183.17"/>
                    <measurement group_id="O2" value="2616.5" spread="6177.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 15, n=58, 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247.6" spread="1123.98"/>
                    <measurement group_id="O2" value="386.0" spread="1474.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1,n=56, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.1" spread="397.94"/>
                    <measurement group_id="O2" value="510.7" spread="1717.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 15,n=56, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" spread="146.90"/>
                    <measurement group_id="O2" value="364.2" spread="1249.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1,n=56, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6" spread="158.45"/>
                    <measurement group_id="O2" value="189.8" spread="550.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1,n=50, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" spread="102.96"/>
                    <measurement group_id="O2" value="101.0" spread="389.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1,n=48, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" spread="83.88"/>
                    <measurement group_id="O2" value="227.4" spread="1027.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1,n=46, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="32.69"/>
                    <measurement group_id="O2" value="763.5" spread="3918.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M, FU, n=53, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="21.30"/>
                    <measurement group_id="O2" value="990.0" spread="5361.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 M, FU, n=58, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1" spread="259.54"/>
                    <measurement group_id="O2" value="194.7" spread="747.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 M, FU, n=49, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" spread="64.26"/>
                    <measurement group_id="O2" value="40.3" spread="33.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 M, FU, n=44, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.3" spread="403.90"/>
                    <measurement group_id="O2" value="83.1" spread="108.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 M, FU, n=36, 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4" spread="255.09"/>
                    <measurement group_id="O2" value="244.9" spread="781.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 M, FU, n=27, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.9" spread="62.99"/>
                    <measurement group_id="O2" value="78.6" spread="52.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 M, FU, n=17, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.9" spread="211.75"/>
                    <measurement group_id="O2" value="95.2" spread="74.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 M, FU, n=17, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="455.1" spread="1487.27"/>
                    <measurement group_id="O2" value="114.7" spread="99.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 M, FU, n=6, 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8" spread="44.76"/>
                    <measurement group_id="O2" value="117.6" spread="70.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>27 M, FU, n=4, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.0" spread="67.93"/>
                    <measurement group_id="O2" value="88.7" spread="43.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 M, FU, n=4, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" spread="62.58"/>
                    <measurement group_id="O2" value="92.0">No standard deviation was able to be calculated for this data point because only one participant was analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>33 M, FU, n=2, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="10.61"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed for this time point therefore there is no data point to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 M, FU, n=2, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.5" spread="122.33"/>
                    <measurement group_id="O2" value="NA">No participants were analyzed for this time point therefore there is no data point to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>39 M, FU, n=1, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0">No standard deviation was able to be calculated for this data point because only one participant was analyzed.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed for this time point therefore there is no data point to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>42 M, FU, n=1, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0">No standard deviation was able to be calculated for this data point because only one participant was analyzed.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed for this time point therefore there is no data point to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 M, FU, n=1, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0">No standard deviation was able to be calculated for this data point because only one participant was analyzed.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed for this time point therefore there is no data point to present.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prognostic and Biological Markers Correlating With Clinical Response</title>
        <description>Blood samples were collected for the assessment of the following prognostic markers at BL: immunoglobulin heavy chain variable region(IgVH) homology; Zeta-Chain-Associated Protein Kinase 70(ZAP70), VH3-21 usage; Cytogenetics (by fluorescent in situ hybridization [FISH]); beta 2 microglobulin. Cox-regression model was used to explore the relationship between progression-free survival and the following explanatory variables: treatment group, cytogenetics (analyzed by FISH included 6q-,11q-, +12q, 17p-, 13q-) , ZAP-70 (positive, negative or intermediate), VH3-21 usage (Yes and No), IgVH homology (&gt;98%, 97%-98% and &lt;97%), beta 2 microglobulin (&gt;3500 microgram per liter [µg/L] and &lt;=3500 µg/L). For each covariate, a hazard ratio &lt;1 indicates a lower risk on the first effect tested compared with the other effects tested. Cytogenetics Group (based on &gt;=20%)=cytogenetics (CY G).</description>
        <time_frame>From randomization up to 5 years after last dose of study drug</time_frame>
        <population>ITT Population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Prognostic and Biological Markers Correlating With Clinical Response</title>
          <description>Blood samples were collected for the assessment of the following prognostic markers at BL: immunoglobulin heavy chain variable region(IgVH) homology; Zeta-Chain-Associated Protein Kinase 70(ZAP70), VH3-21 usage; Cytogenetics (by fluorescent in situ hybridization [FISH]); beta 2 microglobulin. Cox-regression model was used to explore the relationship between progression-free survival and the following explanatory variables: treatment group, cytogenetics (analyzed by FISH included 6q-,11q-, +12q, 17p-, 13q-) , ZAP-70 (positive, negative or intermediate), VH3-21 usage (Yes and No), IgVH homology (&gt;98%, 97%-98% and &lt;97%), beta 2 microglobulin (&gt;3500 microgram per liter [µg/L] and &lt;=3500 µg/L). For each covariate, a hazard ratio &lt;1 indicates a lower risk on the first effect tested compared with the other effects tested. Cytogenetics Group (based on &gt;=20%)=cytogenetics (CY G).</description>
          <population>ITT Population. Only those participants available at the specified time points were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B2 Microglobulin G 1: &gt; 3500 microgram/liter (μg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B2 Microglobulin G 1: &lt;= 3500 ug/L, n=51,47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CY G 1: 11q-, n=40, 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CY G 1: 17p-, n=7, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CY G 1: 6q- or +12q or 13q-, n=84, 80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CY G 1: no aberration, n=45, 47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VH3-21 Usage Flag: Yes, n=9, 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VH3-21 Usage Flag: No, n=159, 162</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgVH Homology, &lt;97%, n=40, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgVH Homology, 97%-98%, n=12, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgVH Homology, &gt;98%, n=115, 116</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ZAP70 G 1, Negative, n=28, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ZAP70 G 1, Intermediate, n=54, 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ZAP70, G1 Positive, n=94, 91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Patient Reported Outcome (PRO) Measures and Scores for European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Chronic Lymphocytic Leukaemia 16 Item Module (EORTC QLQ-CLL 16)</title>
        <description>The EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life (HRQoL) important in CLL. There are 4 multi-item scales – fatigue (2 items), treatment side effects ([TSE], 4 items), disease symptoms (disease effects scale [DES], 4 items), and infection scale [IS] (4 items) – and single item scales (social activities [Social Problems (SP) Scale] and future health worries[Future Health (FH) Scale].). These are measured on a four point scale where 1 = not at all and 4 = very much. These scores are transformed to give a rating from 0 – 100, where 0 =no symptoms or problems and 100 = a severe symptoms or problems. EORTC QLQ-CLL16 was assessed at Screening; Cycle 4 Day 1 and during follow-up 1 M and every 3 M up to 24 months. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value was obtained at randomization.</description>
        <time_frame>Screening, Cycle 3 Day 1, and 1 M and every 3 month post last dose up to 24 month.</time_frame>
        <population>Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Patient Reported Outcome (PRO) Measures and Scores for European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Chronic Lymphocytic Leukaemia 16 Item Module (EORTC QLQ-CLL 16)</title>
          <description>The EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life (HRQoL) important in CLL. There are 4 multi-item scales – fatigue (2 items), treatment side effects ([TSE], 4 items), disease symptoms (disease effects scale [DES], 4 items), and infection scale [IS] (4 items) – and single item scales (social activities [Social Problems (SP) Scale] and future health worries[Future Health (FH) Scale].). These are measured on a four point scale where 1 = not at all and 4 = very much. These scores are transformed to give a rating from 0 – 100, where 0 =no symptoms or problems and 100 = a severe symptoms or problems. EORTC QLQ-CLL16 was assessed at Screening; Cycle 4 Day 1 and during follow-up 1 M and every 3 M up to 24 months. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Baseline value was obtained at randomization.</description>
          <population>Participants</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DES, Cycle 4 Day 1, n=142,125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="18.08"/>
                    <measurement group_id="O2" value="-9.0" spread="17.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DES, 1 M, FU, n=138, 123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" spread="19.18"/>
                    <measurement group_id="O2" value="-9.8" spread="19.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DES, 3 M, FU, n=145, 109</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="19.48"/>
                    <measurement group_id="O2" value="-10.9" spread="19.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DES, 6 M, FU, n= 126, 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="17.99"/>
                    <measurement group_id="O2" value="-11.6" spread="18.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DES, 9 M, FU, n=115, 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="20.70"/>
                    <measurement group_id="O2" value="-12.0" spread="17.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DES. 12 M, FU, n=109, 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="18.64"/>
                    <measurement group_id="O2" value="-10.2" spread="16.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DES, 15 M, FU, n=98, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="18.08"/>
                    <measurement group_id="O2" value="-10.2" spread="16.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DES, 18 M, FU, n=90, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="18.53"/>
                    <measurement group_id="O2" value="-11.6" spread="18.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DES, 21 M, FU, n=87, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="18.48"/>
                    <measurement group_id="O2" value="-11.3" spread="17.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DES, 24 M, FU, n=70, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="19.93"/>
                    <measurement group_id="O2" value="-13.6" spread="16.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue Scale (FS), Cycle 4 Day 1, n=142, 125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="22.57"/>
                    <measurement group_id="O2" value="-7.1" spread="24.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FS, 1 M, FU, n=139, 123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="29.16"/>
                    <measurement group_id="O2" value="-6.2" spread="28.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FS, 3 M, FU, n=144, 109</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="26.30"/>
                    <measurement group_id="O2" value="-8.3" spread="30.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FS, 6 M, FU, n=126, 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="25.94"/>
                    <measurement group_id="O2" value="-12.0" spread="25.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FS, 9 M, FU, n= 115, 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="27.08"/>
                    <measurement group_id="O2" value="-10.6" spread="26.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FS. 12 M, FU, n=109, 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="27.26"/>
                    <measurement group_id="O2" value="-8.1" spread="25.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FS, 15 M, FU, n=97, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="22.57"/>
                    <measurement group_id="O2" value="-9.9" spread="24.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FS, 18 M, FU, n=90,59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="23.03"/>
                    <measurement group_id="O2" value="-3.7" spread="33.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FS, 21 M, FU, n=87, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="24.28"/>
                    <measurement group_id="O2" value="-8.2" spread="27.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FS, 24 M, FU, n=69, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="24.19"/>
                    <measurement group_id="O2" value="-8.7" spread="25.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FH, Cycle 4 Day 1, n=141, 123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="32.89"/>
                    <measurement group_id="O2" value="-10.6" spread="27.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FH, 1 M, FU, n=139, 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.3" spread="35.04"/>
                    <measurement group_id="O2" value="-11.9" spread="29.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FH, 3 M, FU, n=145, 107</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.3" spread="33.96"/>
                    <measurement group_id="O2" value="-14.0" spread="32.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FH, 6 M, FU, n=124, 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.4" spread="33.98"/>
                    <measurement group_id="O2" value="-17.7" spread="30.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FH, 9 M, FU, n=113, 81</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.6" spread="33.65"/>
                    <measurement group_id="O2" value="-13.2" spread="34.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FH. 12 M, FU, n=109, 74</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.1" spread="32.80"/>
                    <measurement group_id="O2" value="-14.9" spread="33.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FH, 15 M, FU, n=98, 61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.6" spread="29.14"/>
                    <measurement group_id="O2" value="-14.2" spread="34.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FH, 18 M, FU, n=90, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.9" spread="31.69"/>
                    <measurement group_id="O2" value="-18.4" spread="33.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FH, 21 M, FU, n=87, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.9" spread="28.70"/>
                    <measurement group_id="O2" value="-15.4" spread="29.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FH, 24 M, FU, n=70, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.0" spread="29.58"/>
                    <measurement group_id="O2" value="-17.7" spread="30.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IS, Cycle 4 Day 1, n=142,125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="17.65"/>
                    <measurement group_id="O2" value="-1.4" spread="18.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IS, 1 M, FU, n=138, 122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="22.79"/>
                    <measurement group_id="O2" value="2.7" spread="24.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IS, 3 M, FU, n=144, 109</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="19.42"/>
                    <measurement group_id="O2" value="0.8" spread="20.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IS, 6 M, FU, n=126, 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="18.46"/>
                    <measurement group_id="O2" value="-0.9" spread="20.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IS, 9 M, FU, n=115, 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="18.81"/>
                    <measurement group_id="O2" value="1.4" spread="22.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IS. 12 M, FU, n=109, 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="19.22"/>
                    <measurement group_id="O2" value="2.1" spread="20.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IS, 15 M, FU, n=97, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="17.56"/>
                    <measurement group_id="O2" value="0.3" spread="18.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IS, 18 M, FU, n=89, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="16.04"/>
                    <measurement group_id="O2" value="0.9" spread="19.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IS, 21 M, FU, n=87, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="18.13"/>
                    <measurement group_id="O2" value="2.5" spread="22.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IS, 24 M, FU, n=69, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="18.85"/>
                    <measurement group_id="O2" value="0.5" spread="21.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SP Scale Cycle 4 Day 1, n=141, 125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="25.44"/>
                    <measurement group_id="O2" value="0.3" spread="26.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SP Scale, 1 M, FU, n=137, 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="34.51"/>
                    <measurement group_id="O2" value="0.0" spread="35.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SP Scale, 3 M, FU, n=143, 109</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="33.04"/>
                    <measurement group_id="O2" value="-4.3" spread="35.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SP Scale, 6 M, FU, n=124, 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="31.73"/>
                    <measurement group_id="O2" value="-10.9" spread="30.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SP Scale, 9 M, FU, n=114, 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="30.15"/>
                    <measurement group_id="O2" value="-11.0" spread="31.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SP Scale. 12 M, FU, n=107, 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="31.06"/>
                    <measurement group_id="O2" value="-7.6" spread="34.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SP Scale, 15 M, FU, n=95, 61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="30.21"/>
                    <measurement group_id="O2" value="-13.7" spread="30.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SP Scale, 18 M, FU, n=89, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="31.57"/>
                    <measurement group_id="O2" value="-8.5" spread="40.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SP Scale, 21 M, FU, n=86, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="31.07"/>
                    <measurement group_id="O2" value="-7.5" spread="37.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SP Scale, 24 M, FU, n=68, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="24.27"/>
                    <measurement group_id="O2" value="-8.7" spread="36.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSE, Cycle 4 Day 1, n=142, 125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="16.15"/>
                    <measurement group_id="O2" value="-4.0" spread="16.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSE, 1 M, FU, n=139, 123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="18.09"/>
                    <measurement group_id="O2" value="-3.2" spread="19.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSE, 3 M, FU, n=145,109</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="19.41"/>
                    <measurement group_id="O2" value="-4.3" spread="17.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSE, 6 M, FU, n=126, 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="15.25"/>
                    <measurement group_id="O2" value="-4.8" spread="16.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSE, 9 M, FU, n=115, 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="17.22"/>
                    <measurement group_id="O2" value="-5.1" spread="16.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSE. 12 M, FU, n=109, 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="16.44"/>
                    <measurement group_id="O2" value="-3.2" spread="13.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSE, 15 M, FU, n=98, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="14.92"/>
                    <measurement group_id="O2" value="-4.2" spread="13.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSE, 18 M, FU, n=90, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="17.10"/>
                    <measurement group_id="O2" value="-3.6" spread="19.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSE, 21 M, FU, n=87, 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="16.63"/>
                    <measurement group_id="O2" value="-4.0" spread="15.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSE, 24 M, FU, n=70, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="17.52"/>
                    <measurement group_id="O2" value="-6.5" spread="14.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Reported Outcome (PRO) as Assessed by EuroQoL Five-Dimension (EQ-5D) Score at Indicated Visit</title>
        <description>EQ-5D is comprised of a 5-item health status measure and a visual analogue scale (VAS) and is used to generate two scores: the utility score and the thermometer score. The utility score measures mobility, self-care, usual activities, pain, discomfort, and anxiety/depression. Responses to each of the 5 health states are measured on a 3-point scale (level 1 = no problem; level 2 = some or moderate problem(s) and level 3 = unable, or extreme problems). Responses are typically converted into health utilities or valuations on a scale ranging from 0 (death) to 1 (perfect health). The thermometer score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A Negative health status describes health state worse than death.Baseline is the most recent, non-missing value prior to or on the first study drug dose date.</description>
        <time_frame>Screening, Cycle 3 Day 1, and 1 M and every 3 month post last dose up to 24 month.</time_frame>
        <population>ITT Population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Reported Outcome (PRO) as Assessed by EuroQoL Five-Dimension (EQ-5D) Score at Indicated Visit</title>
          <description>EQ-5D is comprised of a 5-item health status measure and a visual analogue scale (VAS) and is used to generate two scores: the utility score and the thermometer score. The utility score measures mobility, self-care, usual activities, pain, discomfort, and anxiety/depression. Responses to each of the 5 health states are measured on a 3-point scale (level 1 = no problem; level 2 = some or moderate problem(s) and level 3 = unable, or extreme problems). Responses are typically converted into health utilities or valuations on a scale ranging from 0 (death) to 1 (perfect health). The thermometer score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A Negative health status describes health state worse than death.Baseline is the most recent, non-missing value prior to or on the first study drug dose date.</description>
          <population>ITT Population. Only those participants available at the specified time points were analyzed.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>UT, Cycle 4 Day 1, n=136, 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.27"/>
                    <measurement group_id="O2" value="0.0" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UT, 1 M, FU, n=133, 117</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.22"/>
                    <measurement group_id="O2" value="0.0" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UT, 3 M, FU, n=141, 102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.27"/>
                    <measurement group_id="O2" value="0.1" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UT, 6 M, FU, n=122, 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.24"/>
                    <measurement group_id="O2" value="0.1" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UT, 9 M, FU, n=110, 81</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.26"/>
                    <measurement group_id="O2" value="0.1" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UT. 12 M, FU, n=107, 71</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.21"/>
                    <measurement group_id="O2" value="0.1" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UT, 15 M, FU, n=96, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.23"/>
                    <measurement group_id="O2" value="0.1" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UT, 18 M, FU, n=88, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.21"/>
                    <measurement group_id="O2" value="0.0" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UT, 21 M, FU, n= 87, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.21"/>
                    <measurement group_id="O2" value="0.1" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UT, 24 M, FU, n=68, 47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.19"/>
                    <measurement group_id="O2" value="0.1" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS Cycle 4 Day 1, n=137, 122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="17.68"/>
                    <measurement group_id="O2" value="5.6" spread="17.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS, 1 M, FU, n=138, 122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="20.73"/>
                    <measurement group_id="O2" value="5.9" spread="22.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS, 3 M, FU, n=141, 107</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="19.92"/>
                    <measurement group_id="O2" value="9.6" spread="20.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS, 6 M, FU, n=124, 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="18.84"/>
                    <measurement group_id="O2" value="11.1" spread="19.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS, 9 M, FU, n=114, 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="18.33"/>
                    <measurement group_id="O2" value="11.9" spread="20.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS. 12 M, FU, n=108, 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="21.93"/>
                    <measurement group_id="O2" value="10.3" spread="21.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS, 15 M, FU, n=95, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="17.52"/>
                    <measurement group_id="O2" value="13.1" spread="21.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS, 18 M, FU, n=89, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="17.86"/>
                    <measurement group_id="O2" value="11.1" spread="25.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS, 21 M, FU, n=87, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="16.42"/>
                    <measurement group_id="O2" value="11.3" spread="24.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS, 24 M, FU, n=69, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="19.50"/>
                    <measurement group_id="O2" value="15.2" spread="21.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Score</title>
        <description>EORTC QLQ-C30, a self-reported, cancer-specific instrument assessing 15 domains: physical, role, emotional, cognitive and social functioning, pain,fatigue, nausea and vomiting, insomnia, loss of appetite, constipation, diarrhea, and dyspnea, financial difficulties and a global health status/quality of life (QOF). Functional and symptoms scales were measured on four point Likert scale where 1 = not at all and 4 = very much. Pat. assessed at Screening; Cycle 4 Day 1 and during follow-up 1 M and every 3 M up to 24 months. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Clinically meaningful changes or minimally important differences (MIDs)have been previously established for the EORTC QLQ C30, and categorized as ‘small’ if the mean change in scores is 5-10 points, ‘moderate’ if 10-20 points, and ‘large’ if &gt;20points.</description>
        <time_frame>Screening, Cycle 3 Day 1, and 1 M and every 3 month post last dose up to 24 month.</time_frame>
        <population>ITT Population. Only those participants available at the specified time points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Score</title>
          <description>EORTC QLQ-C30, a self-reported, cancer-specific instrument assessing 15 domains: physical, role, emotional, cognitive and social functioning, pain,fatigue, nausea and vomiting, insomnia, loss of appetite, constipation, diarrhea, and dyspnea, financial difficulties and a global health status/quality of life (QOF). Functional and symptoms scales were measured on four point Likert scale where 1 = not at all and 4 = very much. Pat. assessed at Screening; Cycle 4 Day 1 and during follow-up 1 M and every 3 M up to 24 months. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Clinically meaningful changes or minimally important differences (MIDs)have been previously established for the EORTC QLQ C30, and categorized as ‘small’ if the mean change in scores is 5-10 points, ‘moderate’ if 10-20 points, and ‘large’ if &gt;20points.</description>
          <population>ITT Population. Only those participants available at the specified time points were analyzed</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Appetite Loss, Cycle 4 Day 1, n=140, 124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="25.60"/>
                    <measurement group_id="O2" value="-1.9" spread="26.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite Loss, 1 M, FU, n=136, 119</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="26.14"/>
                    <measurement group_id="O2" value="-3.9" spread="28.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite Loss, 3 M, FU, n=142, 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="26.77"/>
                    <measurement group_id="O2" value="-7.4" spread="28.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite Loss, 6 M, FU, n=123, 97</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="23.00"/>
                    <measurement group_id="O2" value="-12.4" spread="26.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite Loss, 9 M, FU, n=112, 83</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="20.38"/>
                    <measurement group_id="O2" value="-9.6" spread="25.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite Loss. 12 M, FU, n=107, 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="22.76"/>
                    <measurement group_id="O2" value="-6.0" spread="27.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite Loss, 15 M, FU, n=96, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="23.13"/>
                    <measurement group_id="O2" value="-9.4" spread="28.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite Loss, 18 M, FU, n=89, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="20.11"/>
                    <measurement group_id="O2" value="-9.4" spread="30.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite Loss, 21 M, FU, n=87, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="20.36"/>
                    <measurement group_id="O2" value="-7.7" spread="27.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite Loss, 24 M, FU, n=69, 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="22.53"/>
                    <measurement group_id="O2" value="-12.5" spread="29.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning, Cycle 4 Day 1, n=142, 126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="18.25"/>
                    <measurement group_id="O2" value="2.5" spread="18.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning, 1 M, FU, n=139, 122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="18.40"/>
                    <measurement group_id="O2" value="3.0" spread="19.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning, 3 M, FU, n= 145, 109</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="18.74"/>
                    <measurement group_id="O2" value="2.3" spread="21.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning, 6 M, FU, n=126, 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="18.95"/>
                    <measurement group_id="O2" value="2.7" spread="20.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning, 9 M, FU, n=115, 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="20.58"/>
                    <measurement group_id="O2" value="2.4" spread="19.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning. 12 M, FU, n=110, 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="19.17"/>
                    <measurement group_id="O2" value="-1.8" spread="21.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning, 15 M, FU, n=97, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="17.97"/>
                    <measurement group_id="O2" value="0.3" spread="20.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning, 18 M, FU, n=89, 61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="20.00"/>
                    <measurement group_id="O2" value="-0.3" spread="22.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning, 21 M, FU, n=88, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="21.65"/>
                    <measurement group_id="O2" value="-1.9" spread="21.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning, 24 M, FU, n=70, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="20.83"/>
                    <measurement group_id="O2" value="-1.3" spread="21.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation, Cycle 4 Day 1, n=142, 126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="21.46"/>
                    <measurement group_id="O2" value="0.8" spread="18.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation, 1 M, FU, n=139, 122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="19.02"/>
                    <measurement group_id="O2" value="0.3" spread="18.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation, 3 M, FU, n= 145, 109</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="19.33"/>
                    <measurement group_id="O2" value="-0.9" spread="20.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation, 6 M, FU, n=125, 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="19.32"/>
                    <measurement group_id="O2" value="0.3" spread="18.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation, 9 M, FU, n=115, 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="19.71"/>
                    <measurement group_id="O2" value="0.4" spread="18.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation. 12 M, FU, n=109, 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="23.13"/>
                    <measurement group_id="O2" value="0.4" spread="19.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation, 15 M, FU, n=96, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="21.29"/>
                    <measurement group_id="O2" value="-3.8" spread="20.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation, 18 M, FU, n=90, 61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="21.49"/>
                    <measurement group_id="O2" value="-1.1" spread="24.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation, 21 M, FU, n=87, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="22.93"/>
                    <measurement group_id="O2" value="-3.8" spread="23.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation, 24 M, FU, n=70, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="21.23"/>
                    <measurement group_id="O2" value="-3.3" spread="21.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea, Cycle 4 Day 1,n= 141, 125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="19.72"/>
                    <measurement group_id="O2" value="-2.4" spread="17.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea, 1 M, FU, n=135, 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="20.87"/>
                    <measurement group_id="O2" value="0.8" spread="21.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea, 3 M, FU, n=143, 109</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="22.49"/>
                    <measurement group_id="O2" value="1.5" spread="20.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea, 6 M, FU, n=124, 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="20.38"/>
                    <measurement group_id="O2" value="-3.1" spread="16.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea, 9 M, FU, n=114, 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="20.56"/>
                    <measurement group_id="O2" value="-2.7" spread="17.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea. 12 M, FU, n=108, 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="15.75"/>
                    <measurement group_id="O2" value="-2.2" spread="19.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea, 15 M, FU, n=96, 61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="19.57"/>
                    <measurement group_id="O2" value="-4.4" spread="20.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea, 18 M, FU, n=89, 61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="17.67"/>
                    <measurement group_id="O2" value="-1.1" spread="17.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea, 21 M, FU, n=87, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="18.88"/>
                    <measurement group_id="O2" value="0.6" spread="21.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea, 24 M, FU, n=68, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="17.02"/>
                    <measurement group_id="O2" value="-0.7" spread="20.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea Cycle 4 Day 1,n= 138, 124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="22.85"/>
                    <measurement group_id="O2" value="-4.6" spread="23.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea, 1 M, FU, n=139, 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="26.60"/>
                    <measurement group_id="O2" value="-2.8" spread="25.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea, 3 M, FU, n=141, 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="26.40"/>
                    <measurement group_id="O2" value="-1.5" spread="25.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea, 6 M, FU, n=124, 97</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="21.92"/>
                    <measurement group_id="O2" value="-7.2" spread="24.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea, 9 M, FU, n=113, 83</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="26.03"/>
                    <measurement group_id="O2" value="-6.4" spread="23.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea. 12 M, FU, n=108, 73</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="24.52"/>
                    <measurement group_id="O2" value="-4.1" spread="22.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea, 15 M, FU, n=95, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="20.77"/>
                    <measurement group_id="O2" value="-2.2" spread="26.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea, 18 M, FU, n=90, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="24.81"/>
                    <measurement group_id="O2" value="-2.8" spread="29.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea, 21 M, FU, n=87, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="24.92"/>
                    <measurement group_id="O2" value="-1.9" spread="21.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea, 24 M, FU, n=69, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="26.39"/>
                    <measurement group_id="O2" value="-4.8" spread="24.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Functioning Cycle 4 Day 1, n=142, 125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="17.91"/>
                    <measurement group_id="O2" value="5.4" spread="19.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Functioning, 1 M, FU, n=139, 122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="20.26"/>
                    <measurement group_id="O2" value="7.2" spread="24.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Functioning, 3 M, FU, n=145, 109</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="20.93"/>
                    <measurement group_id="O2" value="7.8" spread="20.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Functioning, 6 M, FU, n=126, 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="22.57"/>
                    <measurement group_id="O2" value="8.9" spread="22.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Functioning, 9 M, FU, n=115, 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="22.95"/>
                    <measurement group_id="O2" value="6.7" spread="18.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Functioning. 12 M, FU, n=110, 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="22.11"/>
                    <measurement group_id="O2" value="8.0" spread="21.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Functioning, 15 M, FU, n=98, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="21.54"/>
                    <measurement group_id="O2" value="6.5" spread="21.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Functioning, 18 M, FU, n=90, 61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="22.94"/>
                    <measurement group_id="O2" value="6.5" spread="26.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Functioning, 21 M, FU, n=88, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="22.43"/>
                    <measurement group_id="O2" value="7.7" spread="23.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Functioning, 24 M, FU, n=70, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="23.02"/>
                    <measurement group_id="O2" value="7.1" spread="26.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue Cycle 4 Day 1, n=142, 126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="21.37"/>
                    <measurement group_id="O2" value="-6.3" spread="22.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, 1 M, FU, n=138, 122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.4" spread="25.16"/>
                    <measurement group_id="O2" value="-4.5" spread="28.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, 3 M, FU, n=145, 109</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="24.01"/>
                    <measurement group_id="O2" value="-9.3" spread="27.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, 6 M, FU, n=126, 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="23.64"/>
                    <measurement group_id="O2" value="-12.2" spread="22.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, 9 M, FU, n=115, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="23.80"/>
                    <measurement group_id="O2" value="-9.8" spread="24.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue. 12 M, FU, n=110, 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="25.28"/>
                    <measurement group_id="O2" value="-10.3" spread="23.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, 15 M, FU, n=97, 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="19.83"/>
                    <measurement group_id="O2" value="-8.9" spread="27.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, 18 M, FU, n=90, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="22.25"/>
                    <measurement group_id="O2" value="-6.1" spread="30.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, 21 M, FU, n=88, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" spread="20.44"/>
                    <measurement group_id="O2" value="-9.1" spread="25.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, 24 M, FU, n=70, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.1" spread="23.01"/>
                    <measurement group_id="O2" value="-11.7" spread="25.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial Difficulties Cycle 4 Day 1, n=141, 126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="23.98"/>
                    <measurement group_id="O2" value="-6.1" spread="29.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial Difficulties, 1 M, FU, n=136, 122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="26.57"/>
                    <measurement group_id="O2" value="-5.2" spread="26.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial Difficulties, 3 M, FU, n=145, 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="28.30"/>
                    <measurement group_id="O2" value="-9.0" spread="29.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial Difficulties, 6 M, FU, n=126, 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="24.61"/>
                    <measurement group_id="O2" value="-8.8" spread="26.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial Difficulties, 9 M, FU, n=114, 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="27.54"/>
                    <measurement group_id="O2" value="-8.7" spread="27.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial Difficulties. 12 M, FU, n=110, 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" spread="24.93"/>
                    <measurement group_id="O2" value="-9.6" spread="28.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial Difficulties, 15 M, FU, n=96, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="23.69"/>
                    <measurement group_id="O2" value="-9.7" spread="27.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial Difficulties, 18 M, FU, n=90, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="24.39"/>
                    <measurement group_id="O2" value="-12.2" spread="30.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial Difficulties, 21 M, FU, n=88, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.6" spread="22.34"/>
                    <measurement group_id="O2" value="-11.1" spread="28.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial Difficulties, 24 M, FU, n=70, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="24.93"/>
                    <measurement group_id="O2" value="-12.0" spread="27.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and Vomiting Cycle 4 Day 1, n=142, 126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="16.06"/>
                    <measurement group_id="O2" value="3.7" spread="18.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and Vomiting, 1 M, FU, n=139, 122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="14.85"/>
                    <measurement group_id="O2" value="0.1" spread="19.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and Vomiting, 3 M, FU, n=145, 109</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="15.90"/>
                    <measurement group_id="O2" value="-2.9" spread="14.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and Vomiting, 6 M, FU, n=126, 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="13.12"/>
                    <measurement group_id="O2" value="-2.5" spread="14.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and Vomiting, 9 M, FU, n=115, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="13.81"/>
                    <measurement group_id="O2" value="-1.2" spread="15.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and Vomiting. 12 M, FU, n=110, 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="13.52"/>
                    <measurement group_id="O2" value="-1.8" spread="12.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and Vomiting, 15 M, FU, n=97, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="11.45"/>
                    <measurement group_id="O2" value="-2.7" spread="11.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and Vomiting, 18 M, FU, n=90, 61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="12.03"/>
                    <measurement group_id="O2" value="-2.5" spread="10.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and Vomiting, 21 M, FU, n=88, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="13.37"/>
                    <measurement group_id="O2" value="1.3" spread="11.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea and Vomiting, 24 M, FU, n=70, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="13.69"/>
                    <measurement group_id="O2" value="-0.3" spread="11.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Cycle 4 Day 1, n=142, 126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="20.64"/>
                    <measurement group_id="O2" value="-4.2" spread="20.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, 1 M, FU, n=139, 122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="23.02"/>
                    <measurement group_id="O2" value="-5.5" spread="22.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, 3 M, FU, n=145, 109</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="25.13"/>
                    <measurement group_id="O2" value="-2.1" spread="24.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, 6 M, FU, n=126, 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="23.54"/>
                    <measurement group_id="O2" value="-6.6" spread="20.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, 9 M, FU, n=115, 86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="23.86"/>
                    <measurement group_id="O2" value="-4.8" spread="22.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain. 12 M, FU, n=110, 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="24.43"/>
                    <measurement group_id="O2" value="-3.7" spread="21.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, 15 M, FU, n=98, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="23.08"/>
                    <measurement group_id="O2" value="-3.5" spread="22.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, 18 M, FU, n=90, 61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="19.39"/>
                    <measurement group_id="O2" value="0.5" spread="28.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, 21 M, FU, n=88, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="19.74"/>
                    <measurement group_id="O2" value="-0.9" spread="25.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, 24 M, FU, n=70, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="23.25"/>
                    <measurement group_id="O2" value="-3.0" spread="24.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning Cycle 4 Day 1, n=141, 124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="14.50"/>
                    <measurement group_id="O2" value="0.6" spread="16.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning, 1 M, FU, n=139, 122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="19.52"/>
                    <measurement group_id="O2" value="-0.7" spread="21.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning, 3 M, FU, n=142, 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="18.66"/>
                    <measurement group_id="O2" value="0.9" spread="19.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning, 6 M, FU, n=124, 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="16.41"/>
                    <measurement group_id="O2" value="5.7" spread="17.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning, 9 M, FU, n=113, 83</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="17.30"/>
                    <measurement group_id="O2" value="6.2" spread="17.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning. 12 M, FU, n=109, 73</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="17.98"/>
                    <measurement group_id="O2" value="3.5" spread="17.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning, 15 M, FU, n=96, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="14.65"/>
                    <measurement group_id="O2" value="2.7" spread="18.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning, 18 M, FU, n=90, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="16.65"/>
                    <measurement group_id="O2" value="0.1" spread="22.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning, 21 M, FU, n=88, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="17.14"/>
                    <measurement group_id="O2" value="2.1" spread="18.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning, 24 M, FU, n=69, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="17.44"/>
                    <measurement group_id="O2" value="3.7" spread="20.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Health Status Cycle 4 Day 1, n=140, 122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="23.46"/>
                    <measurement group_id="O2" value="6.8" spread="17.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Health Status, 1 M, FU, n=136, 119</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="24.23"/>
                    <measurement group_id="O2" value="6.9" spread="26.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Health Status, 3 M, FU, n=142, 105</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="21.45"/>
                    <measurement group_id="O2" value="12.3" spread="21.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Health Status, 6 M, FU, n=125, 97</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="21.57"/>
                    <measurement group_id="O2" value="13.7" spread="23.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Health Status, 9 M, FU, n=112, 83</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="23.24"/>
                    <measurement group_id="O2" value="11.7" spread="22.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Health Status. 12 M, FU, n=110, 74</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="23.64"/>
                    <measurement group_id="O2" value="12.2" spread="21.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Health Status, 15 M, FU, n=93, 61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="20.40"/>
                    <measurement group_id="O2" value="12.7" spread="22.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Health Status, 18 M, FU, n= 89, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="23.03"/>
                    <measurement group_id="O2" value="10.4" spread="27.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Health Status, 21 M, FU, n=87, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="20.26"/>
                    <measurement group_id="O2" value="12.7" spread="21.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Health Status, 24 M, FU, n=68, 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="24.28"/>
                    <measurement group_id="O2" value="12.3" spread="24.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning Cycle 4 Day 1,n=140, 124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="23.27"/>
                    <measurement group_id="O2" value="0.1" spread="24.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning, 1 M, FU, n= 138, 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="25.83"/>
                    <measurement group_id="O2" value="-0.7" spread="27.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning, 3 M, FU, n=141, 107</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="25.19"/>
                    <measurement group_id="O2" value="0.9" spread="28.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning, 6 M, FU, n=124, 97</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="25.49"/>
                    <measurement group_id="O2" value="5.5" spread="26.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning, 9 M, FU, n=113, 83</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="26.21"/>
                    <measurement group_id="O2" value="6.2" spread="25.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning. 12 M, FU, n=109, 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="26.46"/>
                    <measurement group_id="O2" value="3.9" spread="24.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning, 15 M, FU, n=96, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="24.84"/>
                    <measurement group_id="O2" value="1.9" spread="25.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning, 18 M, FU, n=90, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="24.09"/>
                    <measurement group_id="O2" value="-0.0" spread="28.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning, 21 M, FU, n=88, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="22.82"/>
                    <measurement group_id="O2" value="2.6" spread="26.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning, 24 M, FU, n=69, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="25.54"/>
                    <measurement group_id="O2" value="3.7" spread="30.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning Cycle 4 Day 1, n=142, 126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="20.30"/>
                    <measurement group_id="O2" value="-0.9" spread="23.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning, 1 M, FU, n=138, 122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="25.98"/>
                    <measurement group_id="O2" value="0.8" spread="27.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning, 3 M, FU, n=145, 109</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="23.76"/>
                    <measurement group_id="O2" value="4.3" spread="26.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning, 6 M, FU, n= 126, 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="22.04"/>
                    <measurement group_id="O2" value="6.1" spread="26.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning, 9 M, FU, n=115, 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="21.84"/>
                    <measurement group_id="O2" value="4.2" spread="25.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning. 12 M, FU, n= 110, 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="23.04"/>
                    <measurement group_id="O2" value="3.3" spread="21.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning, 15 M, FU, n=96, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="18.30"/>
                    <measurement group_id="O2" value="1.6" spread="27.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning, 18 M, FU, n=90, 61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="19.78"/>
                    <measurement group_id="O2" value="2.7" spread="29.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning, 21 M, FU, n=88, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="18.83"/>
                    <measurement group_id="O2" value="4.5" spread="24.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning, 24 M, FU, n=70, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="19.60"/>
                    <measurement group_id="O2" value="7.7" spread="24.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia Cycle 4 Day 1, n=138, 123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="26.07"/>
                    <measurement group_id="O2" value="-8.7" spread="26.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia, 1 M, FU, n=135, 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="29.04"/>
                    <measurement group_id="O2" value="-11.1" spread="27.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia, 3 M, FU, n=139, 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="29.64"/>
                    <measurement group_id="O2" value="-13.3" spread="28.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia, 6 M, FU, n=121, 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="26.18"/>
                    <measurement group_id="O2" value="-17.0" spread="25.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia, 9 M, FU, n=112, 81</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="30.53"/>
                    <measurement group_id="O2" value="-13.2" spread="31.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia. 12 M, FU, n=106, 73</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" spread="25.91"/>
                    <measurement group_id="O2" value="-10.5" spread="29.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia, 15 M, FU, n=96, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="29.02"/>
                    <measurement group_id="O2" value="-17.5" spread="26.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia, 18 M, FU, n=89, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="28.32"/>
                    <measurement group_id="O2" value="-15.3" spread="28.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia, 21 M, FU, n=86, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="25.15"/>
                    <measurement group_id="O2" value="-10.3" spread="34.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia, 24 M, FU, n=68, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="33.30"/>
                    <measurement group_id="O2" value="-13.6" spread="35.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean of Health Change Questionnaire (HCQ)</title>
        <description>The HCQ consists of a single question in which the participant is asked if he/she has experienced any change in his/her health overall since beginning the study. For HCQ, values from 1 to 9 were assigned to the 9 responses in the HCQ questionnaire, ranging from 1 for ‘my health is a great deal better’ to 9 for ‘my health is a great deal worse’ since the beginning of the study. Lower scores represent better conditions.</description>
        <time_frame>Screening, Cycle 3 Day 1, and 1 M and every 3 month post last dose up to 24 month.</time_frame>
        <population>ITT Population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
          <group group_id="O2">
            <title>Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean of Health Change Questionnaire (HCQ)</title>
          <description>The HCQ consists of a single question in which the participant is asked if he/she has experienced any change in his/her health overall since beginning the study. For HCQ, values from 1 to 9 were assigned to the 9 responses in the HCQ questionnaire, ranging from 1 for ‘my health is a great deal better’ to 9 for ‘my health is a great deal worse’ since the beginning of the study. Lower scores represent better conditions.</description>
          <population>ITT Population. Only those participants available at the specified time points were analyzed.</population>
          <units>Unit on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 Day 1, n=139, 124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.62"/>
                    <measurement group_id="O2" value="2.8" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M, FU, n=138, 121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="2.05"/>
                    <measurement group_id="O2" value="3.2" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 M, FU, n=141, 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="2.11"/>
                    <measurement group_id="O2" value="2.8" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 M, FU, n=124, 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.76"/>
                    <measurement group_id="O2" value="2.6" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 M, FU, n=112, 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1.78"/>
                    <measurement group_id="O2" value="2.4" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 M, FU, n=108, 74</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1.80"/>
                    <measurement group_id="O2" value="2.5" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 M, FU, n=96, 61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.57"/>
                    <measurement group_id="O2" value="2.3" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 M, FU, n=88, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.67"/>
                    <measurement group_id="O2" value="2.7" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 M, FU, n= 87, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.50"/>
                    <measurement group_id="O2" value="2.3" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 M, FU, n=69, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.76"/>
                    <measurement group_id="O2" value="2.6" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Area Under the Time-concentration Curve (AUC) Curve Over the Dosing Interval (AUC[0-tau]) of Ofatumumab</title>
        <description>Area under the time-concentration curve (AUC) over the dosing interval (AUC[0-tau]) was evaluated. Blood samples were collected from participants who received ofatumumab plus fludarabine and cyclophosphamide predose and 0.5 h after the end of the ofatumumab infusion at treatment Cycle 1 and Cycle 4 (Days 1, 8, and 85). In addition, predose samples were collected prior to ofatumumab administration at Cycles 2, 3, 5, and 6 (Days 29, 57, 113, and 141).</description>
        <time_frame>Cycle 1 Week 1, Cycle 1 Week 2, Cycles 2,3,4,5,6</time_frame>
        <population>PK Population: Participants for whom a pharmacokinetic sample was obtained were analyzed, only participants available at the specified time points were analyzed(represented by n=X in the category titles)</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Area Under the Time-concentration Curve (AUC) Curve Over the Dosing Interval (AUC[0-tau]) of Ofatumumab</title>
          <description>Area under the time-concentration curve (AUC) over the dosing interval (AUC[0-tau]) was evaluated. Blood samples were collected from participants who received ofatumumab plus fludarabine and cyclophosphamide predose and 0.5 h after the end of the ofatumumab infusion at treatment Cycle 1 and Cycle 4 (Days 1, 8, and 85). In addition, predose samples were collected prior to ofatumumab administration at Cycles 2, 3, 5, and 6 (Days 29, 57, 113, and 141).</description>
          <population>PK Population: Participants for whom a pharmacokinetic sample was obtained were analyzed, only participants available at the specified time points were analyzed(represented by n=X in the category titles)</population>
          <units>hour*nanogram/mililiter (h*ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>cycle 1, week 1, n=158</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3554.910" lower_limit="3224.844" upper_limit="3918.759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cycle 1, week 2, n=129</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34109.67" lower_limit="30042.08" upper_limit="38728.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cycle 2, n=147</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67069.79" lower_limit="59485.45" upper_limit="75621.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cycle 3, n=129</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84620.05" lower_limit="76209.86" upper_limit="93958.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cycle 4, 107</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89091.35" lower_limit="78326.34" upper_limit="101335.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cycle 5, n=97</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96829.23" lower_limit="84488.81" upper_limit="110972.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cycle 6, n=91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104798.0" lower_limit="90904.74" upper_limit="120814.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration (Cmax) and Observed Drug Concentration Prior to the Next Dose (Ctrough) of Ofatumumab</title>
        <description>Blood samples were collected to assess the plasma concentration of ofatumumab.Cmax and Ctrough were determined. Blood samples were collected from participants who received ofatumumab plus fludarabine and cyclophosphamide predose and 0.5 h after the end of the ofatumumab infusion at treatment Cycle 1 and Cycle 4 (Days 1, 8, and 85). In addition, predose samples were collected prior to ofatumumab administration at Cycles 2, 3, 5, and 6 (Days 29, 57, 113, and 141).</description>
        <time_frame>Cycle 1 Week 1, Cycle 1 Week 2, Cycles 2,3,4,5</time_frame>
        <population>PK Population: Participants for whom a pharmacokinetic sample was obtained were analyzed, only participants available at the specified time points were analyzed(represented by n=X in the category titles)</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) and Observed Drug Concentration Prior to the Next Dose (Ctrough) of Ofatumumab</title>
          <description>Blood samples were collected to assess the plasma concentration of ofatumumab.Cmax and Ctrough were determined. Blood samples were collected from participants who received ofatumumab plus fludarabine and cyclophosphamide predose and 0.5 h after the end of the ofatumumab infusion at treatment Cycle 1 and Cycle 4 (Days 1, 8, and 85). In addition, predose samples were collected prior to ofatumumab administration at Cycles 2, 3, 5, and 6 (Days 29, 57, 113, and 141).</description>
          <population>PK Population: Participants for whom a pharmacokinetic sample was obtained were analyzed, only participants available at the specified time points were analyzed(represented by n=X in the category titles)</population>
          <units>Micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax cycle 1, week 1, n=154</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.355" lower_limit="55.444" upper_limit="67.897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax cycle 1, week 2, n=159</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241.192" lower_limit="210.492" upper_limit="276.369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax cycle 4, n=140</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312.745" lower_limit="287.708" upper_limit="339.961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctrough cycle 1, week 1, n=167</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.551" lower_limit="2.417" upper_limit="5.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctrough cycle 1, week 2, n=165</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.496" lower_limit="6.565" upper_limit="13.736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctrough cycle 2, n=162</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.281" lower_limit="17.953" upper_limit="32.840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctrough cycle 3,n=150</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.632" lower_limit="18.884" upper_limit="34.791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctrough cycle 4,n=130</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.640" lower_limit="44.465" upper_limit="77.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctrough cycle 5, n=113</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.398" lower_limit="55.257" upper_limit="89.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Occurrence of Cmax (Tmax) of Ofatumumab</title>
        <description>Blood samples were collected from participants who received ofatumumab plus fludarabine and cyclophosphamide predose and 0.5 h after the end of the ofatumumab infusion at treatment Cycle 1 and Cycle 4.</description>
        <time_frame>Cycle 1 Week 1, Cycle 1 Week 2, Cycle 4</time_frame>
        <population>PK Population: Participants for whom a pharmacokinetic sample was obtained were analyzed, only participants available at the specified time points were analyzed(represented by n=X in the category titles)</population>
        <group_list>
          <group group_id="O1">
            <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
            <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Occurrence of Cmax (Tmax) of Ofatumumab</title>
          <description>Blood samples were collected from participants who received ofatumumab plus fludarabine and cyclophosphamide predose and 0.5 h after the end of the ofatumumab infusion at treatment Cycle 1 and Cycle 4.</description>
          <population>PK Population: Participants for whom a pharmacokinetic sample was obtained were analyzed, only participants available at the specified time points were analyzed(represented by n=X in the category titles)</population>
          <units>Hour</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>cycle 1, week 1,n=154</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.106" lower_limit="5.789" upper_limit="6.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cycle 1, week 2, n=159</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.004" lower_limit="4.896" upper_limit="5.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cycle 4, n=140</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.878" lower_limit="4.661" upper_limit="5.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs were collected from 60 days after the last dose of study drug to the end of the follow-up period or until initiation of subsequent, non-study related anti-cancer therapy (up to approximately 5 years after the last dose of study drug).</time_frame>
      <desc>Serious adverse events (SAEs) and non-serious AEs regardless of relationship to study drug were collected from the first dose of study drug to 60 days after the last dose of study drug. SAEs and non-serious AEs were collected in the Safety Population, comprised of all participants who received at least one dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ofatumumab + Fludarabine + Cyclophosphamide</title>
          <description>Participants with relapsed CLL received IV infusions of ofatumumab in combination with fludarabine and cyclophosphamide IV infusions for 6 cycles; each cycle comprised of 28 days. Participants received ofatumumab administered at 300 milligram (mg) on Day 1, 1000 mg on Day 8 of cycle 1 and 1000 mg on Day 1 of cycles 2, 3, 4, 5 and 6. Fludarabine was administered at 25 mg/meter squared [m^2] and cyclophosphamide was administered at 250mg/m^2 on Days 1-3 of each cycles (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
        </group>
        <group group_id="E2">
          <title>Fludarabine + Cyclophosphamide</title>
          <description>Participants with relapsed CLL received IV infusions of fludarabine administered at 25 mg/m^2 and cyclophosphamide administered at 250mg/m^2 on Days 1-3 of each cycle (6 cycles). Participants were followed up one month post therapy and every 3 months for 5 years to evaluate survival and disease status.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Autoimmune haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Aplasia pure red cell</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Epidermolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Functional gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Neutropenic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Acinetobacter bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Acinetobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Atypical mycobacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Gastrointestinal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pneumonia haemophilus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Salmonella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Systemic mycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Starvation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Bladder papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Melanoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Tumour associated fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Demyelinating polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Bronchial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Respiratory tract haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Haemorrhagic vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="150" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Disclosure Office</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

